Dihydropyrazolopyrazinone derivatives having MGAT2 inhibitory activity

Abstract

The present invention relates to a dihydropyrazolopyrazinone derivative having an MGAT2 inhibitory effect, and more specifically, to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. In formula (1), R1 is hydrogen, a hydroxyl group, or the like; r2a and R2b may form a ring B together with an adjacent carbon atom, and ring B is a substituted or unsubstituted non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring; r3a is hydrogen, halogen, hydroxyl or the like; r3b is hydrogen, halogen, hydroxyl or the like; r4a is represented by the following formula (2); l3 is a single bond or a substituted or unsubstituted alkylene group, R7 is hydrogen, halogen, hydroxyl or the like, and R4b is halogen, cyano, carboxyl or the like. # imgabs0 #

Description

This application is a divisional application of the Chinese patent application with application number 202080018835.3 (application date: January 10, 2020, invention name: dihydropyrazolopyrazinone derivatives with MGAT2 inhibitory activity). [Technical field]

[0001] The present invention relates to a compound having a monoacylglycerol acyltransferase 2 (hereinafter also referred to as MGAT2) inhibitory effect, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. [Background technology]

[0002] Obesity is defined as a state of excess body fat or adipose tissue relative to body weight, and is considered a major risk factor for health problems. Body mass index (BMI) is a simple index of height-to-weight ratio commonly used to classify groups or individuals of adults (over 15 years old) as overweight or obese. BMI is defined as weight in kilograms divided by height in meters squared (kg / m 2 ). The World Health Organization defines BMI as 25 kg / m 2 The above is defined as "overweight", 30kg / m 2 The above is defined as "obesity". On the other hand, in Japanese obesity studies, BMI is 25kg / m 2 The above definition is "obesity". This is because the number of obesity-related diseases, including diabetes and dyslipidemia, increases in proportion to BMI, so the average number of diseases is 25 kg / m 2 becomes above 1.0. According to a survey conducted by the World Health Organization in 2005, about 1.6 billion people in the world are overweight and at least 400 million are obese. Obesity is mainly caused by an increase in the ratio of calorie intake to physical activity or daily life. In recent years, the number of obese people has increased due to the increase in the intake of high-fat and high-sugar foods. In 2015, it is predicted that more than 700 million people in the world will be diagnosed with obesity. This type of treatment includes diet therapy, exercise therapy, drug therapy, etc. Drugs such as Orlistat and Mazindol are used in drug therapy, but there is no drug that can take into account both efficacy and side effects. Excessive intake of neutral fat is one of the causes of obesity. Neutral fat (triglyceride) ingested through diet is decomposed into 2-monoacylglycerol and free fatty acids by pancreatic lipase in the digestive tract and absorbed by intestinal epithelial cells. The acyl group of free fatty acids is transferred to 2-monoacylglycerol by monoacylglycerol acyltransferase (MGAT). The generated diacylglycerol is further converted into neutral fat by diacylglycerol acyltransferase (DGAT). MGAT is identified as three isoforms, MGAT1, MGAT2, and MGAT3. Among them, MGAT2 and MGAT3 are highly expressed in the small intestine and are considered to be involved in fat absorption in the small intestine. Experiments conducted with MGAT2 knockout mice have reported that high-fat diet load leads to increased expression of MGAT2 in the small intestine and increased MGAT activity (Non-Patent Document 1). Further, in MGAT2 knockout mice, suppression of weight gain due to high-fat diet load, suppression of insulin resistance induction, suppression of blood cholesterol rise, suppression of fatty liver formation, and hyperactivity of energy consumption have also been confirmed (Non-Patent Document 2). Compounds having MGAT2 inhibitory activity have been reported so far (Patent Documents 1 to 19, Non-Patent Documents 3 to 13), but the compounds of the present invention shown below have not been disclosed. [Background Technology Literature] [Patent Document]

[0003] [Patent Document 1] International Publication No. 2010 / 095767 [Patent Document 2] International Publication No. 2012 / 091010 [Patent Document 3] International Publication No. 2012 / 124744 [Patent Document 4] International Publication No. 2013 / 082345 [Patent Document 5] International Publication No. 2013 / 112323 [Patent Document 6] International Publication No. 2013 / 116065 [Patent Document 7] International Publication No. 2013 / 116075 [Patent Document 8] International Publication No. 2014 / 074365 [Patent Document 9] International Publication No. 2014 / 133134 [Patent Document 10] International Publication No. 2014 / 193884 [Patent Document 11] Japanese Patent Application Laid-Open No. 2014-5245 [Patent Document 12] Japanese Patent Application Laid-Open No. 2014-9165 [Patent Document 13] International Publication No. 2015 / 112465 [Patent Document 14] International Publication No. 2015 / 129845 [Patent Document 15] International Publication No. 2015 / 134699 [Patent Document 16] International Publication No. 2015 / 134701 [Patent Document 17] International Publication No. 2015 / 191681 [Patent Document 18] International Publication No. 2016 / 121782 [Patent Document 19] International Publication No. 2017 / 069224 [Non-patent literature]

[0004] [Non-patent document 1] Journal of Biological Chemistry (2004), 279, 18878-18886 [Non-patent document 2] Nature Medicine (2009), 15, (4), 442-446 [Non-patent document 3] Bioorganic & Medicinal Chemistry Letter (2013), 23, 2721-2726 [Non-patent document 4] Med. Chem. Commun (2013), 4, 1305-1311 [Non-patent document 5] Bioorganic & Medicinal Chemistry Letter (2015), 23, 5922-5931 [Non-patent document 6] Bioorganic & Medicinal Chemistry Letter (2015), 23, 4544-4560 [Non-patent document 7] Journal of Lipid Research 2015, 56, 747-753 [Non-patent document 8] European Journal of Pharmacology, 2015, 758, 72-81 [Non-patent document 9] Journal of Medicinal Chemistry (2015), 58, 3892-3909 [Non-patent document 10] HETEROCYCLES 2016, 92, 470-484 [Non-patent document 11] Chemical and Pharmaceutical Bulletin, 2016, 64, 228-238 [Non-patent document 12] European Journal of Pharmacology, 2016, 791, 569-577 [Non-patent document 13] Analytical Biochemistry, 2016, 501, 48-55 [Summary of the invention] [Problems to be solved by the invention]

[0005] The object of the present invention is to provide a compound having MGAT2 inhibitory effect or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the compound. [Methods to solve the problem]

[0006] The present inventors have studied intensively and succeeded in synthesizing an excellent compound having MGAT2 inhibitory activity. In other words, the present invention relates to the following. [1] A compound represented by formula (I), or a pharmaceutically acceptable salt thereof, (Where, R 1 is hydrogen, hydroxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfonyl, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, substituted or unsubstituted aromatic heterocyclic sulfonyl, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl; R 2a As shown in the following formula: (wherein, ring C is an aromatic carbocycle, an aromatic heterocycle, a non-aromatic carbocycle, or a non-aromatic heterocycle; R 5are each independently halogen, hydroxy, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, a substituted or unsubstituted aromatic carbocyclic sulfide group, a substituted or unsubstituted non-aromatic carbocyclic sulfide group, a substituted or unsubstituted aromatic heterocyclic sulfide group, a substituted or unsubstituted non-aromatic heterocyclic sulfide group, a substituted or unsubstituted aromatic carbocyclic sulfinyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfinyl group, a substituted or unsubstituted aromatic heterocyclic sulfinyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfinyl group, a substituted or unsubstituted aromatic carbocyclic sulfonyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, a substituted or unsubstituted aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted aromatic ... non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfon S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NR N)2-R S1 The base shown, m is an integer from 1 to 5), R 2b is hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted alkylsulfonyl, or R 2a and R 2b It can also form a ring B together with the adjacent carbon atom. Ring B is a substituted or unsubstituted non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring; R 3a is hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic groupoxy, substituted or unsubstituted non-aromatic carbocyclic groupoxy, substituted or unsubstituted aromatic heterocyclic groupoxy, substituted or unsubstituted non-aromatic heterocyclic groupoxy, substituted or unsubstituted aromatic carbocyclic groupsulfonyl, substituted or unsubstituted non-aromatic carbocyclic groupsulfonyl, substituted or unsubstituted aromatic heterocyclic groupsulfonyl, or substituted or unsubstituted non-aromatic heterocyclic groupsulfonyl, R 3b is hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic groupoxy, substituted or unsubstituted non-aromatic carbocyclic groupoxy, substituted or unsubstituted aromatic heterocyclic groupoxy, substituted or unsubstituted non-aromatic heterocyclic groupoxy, substituted or unsubstituted aromatic carbocyclic groupsulfonyl, substituted or unsubstituted non-aromatic carbocyclic groupsulfonyl, substituted or unsubstituted aromatic heterocyclic groupsulfonyl, or substituted or unsubstituted non-aromatic heterocyclic groupsulfonyl, R 3a With R 3b can form a substituted or unsubstituted non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring together with the adjacent carbon atoms, or R 2b With R 3b can form a substituted or unsubstituted non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring together with the adjacent carbon atoms; R 4a As shown in the following formula: L 3 is a single bond or a substituted or unsubstituted alkylene group, R 7 is hydrogen, halogen, hydroxy, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy group substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted a substituted aromatic carbocyclic sulfide group, a substituted or unsubstituted non-aromatic carbocyclic sulfide group, a substituted or unsubstituted aromatic heterocyclic sulfide group, a substituted or unsubstituted non-aromatic heterocyclic sulfide group, a substituted or unsubstituted aromatic carbocyclic sulfinyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfinyl group, a substituted or unsubstituted aromatic heterocyclic sulfinyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfinyl group, a substituted or unsubstituted aromatic carbocyclic sulfonyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, a substituted or unsubstituted aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted aromatic ... non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or un S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NRN )(-R S1 )-R S2 , or formula: -S(=NR N )2-R S1 The base shown, But L 3 When it is a single bond, R 7 is not hydrogen or halogen, R 4bis halogen, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfenyl, substituted or unsubstituted non-aromatic carbocyclic sulfenyl, substituted or unsubstituted aromatic heterocyclic sulfenyl, substituted or unsubstituted non-aromatic heterocyclic sulfenyl, substituted or unsubstituted aromatic carbocyclic sulfinyl, substituted or unsubstituted non-aromatic carbocyclic sulfinyl, substituted or unsubstituted aromatic heterocyclic sulfinyl, substituted or unsubstituted non-aromatic heterocyclic sulfinyl, substituted or unsubstituted aromatic carbocyclic sulfonyl, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, substituted or unsubstituted aromatic heterocyclic sulfonyl, substituted or unsubstituted non-aromatic heterocyclic sulfonyl, formula: -LN=S(=O)(-R S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NR N )2-RS1 The base shown, L is each independently a single bond, an alkylene group, or C(═O), R S1 and R S2 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, or substituted or unsubstituted non-aromatic heterocyclic group, or, R bonded to the same sulfur atom S1 and R S2 is a substituted or unsubstituted non-aromatic heterocyclic ring that can be formed together with the sulfur atom; R N are each independently hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, or substituted or unsubstituted non-aromatic heterocyclic carbonyl). [2] The compound as described in the above [1], or a pharmaceutically acceptable salt thereof, wherein Ring B is represented by any of the following formulae. Mode: (Where, B 1 CR 11a R 11b NR 11c , O, or S, B 2 CR 12a R 12b NR 12c , O, or S, B 3 CR 13a R 13b NR 13c , O, or S, B 4 CR 14a R 14b NR 14c , O, or S, and B 5 CR 15a R 15b NR 15c , O, or S, R 11a , R12a , R 13a , R 14a , and R 15a are each independently hydrogen, halogen, hydroxy, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted substituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, a substituted or unsubstituted aromatic carbocyclic sulfide group, a substituted or unsubstituted non-aromatic carbocyclic sulfide group, a substituted or unsubstituted aromatic heterocyclic sulfide group, a substituted or unsubstituted non-aromatic heterocyclic sulfide group, a substituted or unsubstituted aromatic carbocyclic sulfinyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfinyl group, a substituted or unsubstituted aromatic heterocyclic sulfinyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfinyl group, a substituted or unsubstituted aromatic carbocyclic sulfonyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, a substituted or unsubstituted aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted aromatic ... non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfon S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NRN )(-R S1 )-R S2 , or formula: -S(=NR N )2-R S1 The base shown, R 11b , R 12b , R 13b , R 14b , and R 15bare each independently hydrogen, halogen, hydroxy, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted substituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, a substituted or unsubstituted aromatic carbocyclic sulfide group, a substituted or unsubstituted non-aromatic carbocyclic sulfide group, a substituted or unsubstituted aromatic heterocyclic sulfide group, a substituted or unsubstituted non-aromatic heterocyclic sulfide group, a substituted or unsubstituted aromatic carbocyclic sulfinyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfinyl group, a substituted or unsubstituted aromatic heterocyclic sulfinyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfinyl group, a substituted or unsubstituted aromatic carbocyclic sulfonyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, a substituted or unsubstituted aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted aromatic ... non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfon S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NRN )2-R S1 The base shown, R 11c , R 12c , R 13c , R 14c , and R 15c are each independently hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl a substituted or unsubstituted alkenyloxycarbonyl group, a substituted or unsubstituted alkylthio group, a substituted or unsubstituted alkenylthio group, a substituted or unsubstituted alkylsulfinyl group, a substituted or unsubstituted alkenylsulfinyl group, a substituted or unsubstituted alkylsulfonyl group, a substituted or unsubstituted alkenylsulfonyl group, a substituted or unsubstituted aromatic carbocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic carbocyclic oxy group, a substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic thio, substituted or unsubstituted substituted or unsubstituted non-aromatic carbocyclic sulfenyl, substituted or unsubstituted aromatic heterocyclic sulfenyl, substituted or unsubstituted non-aromatic heterocyclic sulfenyl, substituted or unsubstituted aromatic carbocyclic sulfinyl, substituted or unsubstituted non-aromatic carbocyclic sulfinyl, substituted or unsubstituted aromatic heterocyclic sulfinyl, substituted or unsubstituted non-aromatic heterocyclic sulfinyl, substituted or unsubstituted aromatic carbocyclic sulfonyl, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, substituted or unsubstituted aromatic heterocyclic sulfonyl, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl, or, R 11a With R 12a , R 12a With R 13a , R 13a With R 14a and / or R 14a With R 15acan form a substituted or unsubstituted aromatic carbocyclic ring, a substituted or unsubstituted non-aromatic carbocyclic ring, a substituted or unsubstituted aromatic heterocyclic ring, or a substituted or unsubstituted non-aromatic heterocyclic ring together with adjacent carbon atoms, and / or, R 11c With R 12a , R 11c With R 12c , R 12c With R 11a , R 12c With R 13a , R 12c With R 13c , R 13c With R 12a , R 13c With R 14a , R 13c With R 14c , R 14c With R 13a , R 14c With R 15a , R 14c With R 15c , and / or R 15c With R 14a can form a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle together with adjacent atoms, and / or, R 11a With R 13a , R 11a With R 13c , R 11a With R 14a , R 11a With R 14c , R 11a With R 15a , R 11a With R 15c , R 11c With R 13a , R 11c With R 13c , R 11c With R 14a , R 11c With R 14c , R 11c With R 15a , R 11c With R 15c , R 12a With R 14a , R 12a With R 14c , R 12a With R 15a , R 12a With R 15c , R 12c With R14a , R 12c With R 14c , R 12c With R 15a , R 12c With R 15c , R 13a With R 15a , R 13a With R 15c , R 13c With R 15a , and / or R 13c With R 15c are C2-C4 bridges that can together form a heteroatom insertable therein, and / or R 11b With R 12b , R 11b With R 12c , R 11c With R 12b , R 11c With R 12c , R 12b With R 13b , R 12b With R 13c , R 12c With R 13b , R 12c With R 13c , R 13b With R 14b , R 13b With R 14c , R 13c With R 14b , R 13c With R 14c , R 14b With R 15b , R 14b With R 15c , R 14c With R 15b , and / or R 14c With R 15c To form a bond together, Other symbols have the same meaning as above [1]) [3] The compound described in [1] or [2] above, or a pharmaceutically acceptable salt thereof, wherein Ring B is represented by any of the following formulae. Mode: (Where, B 1 C, CR 11a , or N, B 2 C, CR 12a or N, B 3 CR 13a R 13b NR 13c , O or S, B 4 CR 14a R 14b NR 14c , O or S, B 5 CR 15a R 15b NR 15c , O or S, R 11a , R 12a , R 13a , R 14a , and R 15aare each independently hydrogen, halogen, hydroxy, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted substituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, a substituted or unsubstituted aromatic carbocyclic sulfide group, a substituted or unsubstituted non-aromatic carbocyclic sulfide group, a substituted or unsubstituted aromatic heterocyclic sulfide group, a substituted or unsubstituted non-aromatic heterocyclic sulfide group, a substituted or unsubstituted aromatic carbocyclic sulfinyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfinyl group, a substituted or unsubstituted aromatic heterocyclic sulfinyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfinyl group, a substituted or unsubstituted aromatic carbocyclic sulfonyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, a substituted or unsubstituted aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted aromatic ... non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfon S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NRN )2-R S1 The base shown, R 13b , R 14b , and R 15b are each independently hydrogen, halogen, hydroxy, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted substituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, a substituted or unsubstituted aromatic carbocyclic sulfide group, a substituted or unsubstituted non-aromatic carbocyclic sulfide group, a substituted or unsubstituted aromatic heterocyclic sulfide group, a substituted or unsubstituted non-aromatic heterocyclic sulfide group, a substituted or unsubstituted aromatic carbocyclic sulfinyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfinyl group, a substituted or unsubstituted aromatic heterocyclic sulfinyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfinyl group, a substituted or unsubstituted aromatic carbocyclic sulfonyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, a substituted or unsubstituted aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted aromatic ... non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfon S1 )-R S2 、Formula: -LS(=O)(=NR N )-RS1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NR N )2-R S1 The base shown, R 13c , R 14c , and R 15c are each independently hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group , substituted or unsubstituted aromatic heterocyclic oxy, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic thio, substituted or unsubstituted non-aromatic carbocyclic sulfenyl, substituted or unsubstituted aromatic heterocyclic sulfenyl, substituted or unsubstituted non-aromatic heterocyclic sulfenyl, substituted or unsubstituted aromatic carbocyclic sulfinyl, substituted or unsubstituted non-aromatic carbocyclic sulfinyl, substituted or unsubstituted aromatic heterocyclic sulfinyl, substituted or unsubstituted non-aromatic heterocyclic sulfinyl, substituted or unsubstituted aromatic carbocyclic sulfonyl, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, substituted or unsubstituted aromatic heterocyclic sulfonyl, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl, or, R 11a With R 13a , R 11a With R 13c , R 11a With R14a , R 11a With R 14c , R 11a With R 15a , R 11a With R 15c , R 12a With R 14a , R 12a With R 14c , R 12a With R 15a , R 12a With R 15c , R 13a With R 15a , R 13a With R 15c , R 13c With R 15a , and / or R 13c With R 15c are C2-C4 bridges that can together form a heteroatom insertable therein, and / or R 11a With R 12a , R 12a With R 13b , R 12a With R 13c , R 13b With R 14b , R 13b With R 14c , R 13c With R 14b , R 13c With R 14c , R 14b With R 15b , R 14b With R 15c , R 14c With R 15b , and / or R 14c With R 15c To form a bond together, Ring D is an aromatic carbocyclic ring, a non-aromatic carbocyclic ring, an aromatic heterocyclic ring, or a non-aromatic heterocyclic ring, R 6are each independently halogen, hydroxy, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, a substituted or unsubstituted aromatic carbocyclic sulfide group, a substituted or unsubstituted non-aromatic carbocyclic sulfide group, a substituted or unsubstituted aromatic heterocyclic sulfide group, a substituted or unsubstituted non-aromatic heterocyclic sulfide group, a substituted or unsubstituted aromatic carbocyclic sulfinyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfinyl group, a substituted or unsubstituted aromatic heterocyclic sulfinyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfinyl group, a substituted or unsubstituted aromatic carbocyclic sulfonyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, a substituted or unsubstituted aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted aromatic ... non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfon S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NR N)2-R S1 The base shown, n is an integer from 1 to 4, Other symbols have the same meaning as above [1]) [4] The compound as described in any one of [1] to [3] above, or a pharmaceutically acceptable salt thereof, wherein Ring B is represented by any one of the following formulae. Mode: (Where B 3 , B 4 , B 5 , R 6 and n has the same meaning as in [3] above) [5] The compound as described in any one of [1] to [4] above, or a pharmaceutically acceptable salt thereof, wherein Ring B is represented by any one of the following formulae. Mode: (Where R 6 , R 13a , R 13b , R 14a , R 14b , R 15a , R 15b , and n have the same meaning as in [3] above) [6] The compound as described in [3] or [4] above, or a pharmaceutically acceptable salt thereof, wherein R 6 are each independently halogen, cyano, hydroxy, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl group. [7] The compound as described in any one of [3] to [5] above, or a pharmaceutically acceptable salt thereof, wherein R 6 are each independently halogen, or substituted or unsubstituted alkyloxy. [8] In the compound described in any one of [3] to [5] above, or a pharmaceutically acceptable salt thereof, Ring B is represented by any one of the following formulae. Mode: (Where R 6 are each independently a substituted or unsubstituted alkyloxy group, R 13a , R 13b , R 14a , R 14b , R 15a , and R 15b has the same meaning as above [3]) [9] The compound as described in any one of [3] to [5] above, or a pharmaceutically acceptable salt thereof, wherein Ring B is represented by any one of the following formulae. Mode: (Where R 6 are each independently halogen, or substituted or unsubstituted alkyloxy, R 13a , R 13b , R 14a , R 14b , R 15a , and R 15b has the same meaning as above [3])

[10] The compound as described in the above [1], or a pharmaceutically acceptable salt thereof, wherein Ring C is an aromatic carbocyclic ring or an aromatic heterocyclic ring.

[11] The compound as described in [1] or

[10] above, or a pharmaceutically acceptable salt thereof, wherein R 5 are each independently halogen, cyano, hydroxy, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, m is 1 to 3.

[12] The compound as described in any one of [1],

[10] or

[11] above, or a pharmaceutically acceptable salt thereof, wherein R 2b is a substituted or unsubstituted alkyl group.

[13] The compound as described in any one of [1] to

[12] above, or a pharmaceutically acceptable salt thereof, wherein R 4a For the following bases, (Where, L 3 , and R 7 has the same meaning as above [1].

[14] A compound as described in any one of [1] to

[13] above, or a pharmaceutically acceptable salt thereof, wherein L 3 is a substituted or unsubstituted alkylene group.

[15] The compound as described in

[14] above, or a pharmaceutically acceptable salt thereof, wherein R 7 is halogen, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, or a ... N )-R S1 .

[16] A compound as described in any one of [1] to

[13] above, or a pharmaceutically acceptable salt thereof, wherein L 3 For a single key.

[17] The compound as described in

[16] above, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted non-aromatic heterocyclic group.

[18] The compound as described in any one of [1] to

[17] above, or a pharmaceutically acceptable salt thereof, wherein R 4b is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic heterocyclic group.

[19] The compound as described in any one of [1] to

[18] above, or a pharmaceutically acceptable salt thereof, wherein R 3a and R 3b For hydrogen.

[20] The compound or pharmaceutically acceptable salt thereof as described in [1] above is selected from the group consisting of compounds I-6, I-13, I-14, I-20, I-33, I-46, I-58, I-61, I-66, I-79, I-126, I-130, I-133, I-137 and I-142. [20-1] The compound or pharmaceutically acceptable salt thereof as described in the above [1] is selected from the group consisting of compounds I-123, I-124, I-136, I-139, I-141, I-143, I-145 and I-147. [20-2] The compound or pharmaceutically acceptable salt thereof as described in [1] above, which is selected from the group consisting of compounds I-151 and I-153. [twenty one] A pharmaceutical composition comprising the compound described in any one of [1] to

[20] or [20-1] to [20-2] above or a pharmaceutically acceptable salt thereof. [twenty two] The pharmaceutical composition as described in the aforementioned

[21] has a MGAT2 inhibitory effect. [twenty three] The pharmaceutical composition as described in

[21] or

[22] above is used for treating or preventing a disease associated with MGAT2. [twenty four] A pharmaceutical composition as described in the above-mentioned

[23] , which is used for the treatment or prevention of obesity, metabolic syndrome, hyperlipidemia, high-grade lipidemia, hyperVLDLemia, hyperfatty acidemia, diabetes or arteriosclerosis.

[25] A method for treating or preventing a disease associated with MGAT2, comprising delivering the compound described in any one of [1] to

[20] or [20-1] to [20-2] above, or a pharmaceutically acceptable salt thereof.

[26] A compound as described in any one of [1] to

[20] or [20-1] to [20-2], or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a disease associated with MGAT2.

[27] A use of the compound described in any one of [1] to

[20] or [20-1] to [20-2], or a pharmaceutically acceptable salt thereof, for treating or preventing a disease associated with MGAT2.

[0008] [1'] A compound represented by formula (I), or a pharmaceutically acceptable salt thereof: (Where, R 1 is hydrogen; R 2a and R 2b Together with the adjacent carbon atoms, they form ring B, Ring B is represented by the following formula: (Where R 6are each independently halogen, or substituted or unsubstituted alkyloxy, n is 1 or 2); R 3a is hydrogen; R 3b is hydrogen; R 4a As shown in the following formula: (Where, L 3 is a single bond or a substituted or unsubstituted alkylene group, R 7 is halogen, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, or a group of the formula: -S(=O)(=NR N )-R S1 , R N For hydrogen, R S1 is a substituted or unsubstituted alkyl group); R 4b is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic carbocyclic group, or a substituted or unsubstituted aromatic heterocyclic group). [2'] The compound as described in [1'] above, or a pharmaceutically acceptable salt thereof, wherein Ring B is represented by any of the following formulae. Mode: (Where R 6 are each independently substituted or unsubstituted alkyloxy) [3'] The compound as described in [1'] above, or a pharmaceutically acceptable salt thereof, wherein Ring B is represented by any of the following formulae. Mode: (Where R 6 are each independently halogen, or substituted or unsubstituted alkyloxy) [4'] The compound as described in any one of [1'] to [3'] above, or a pharmaceutically acceptable salt thereof, wherein L 3 is a substituted or unsubstituted alkylene group. [5'] The compound as described in [4'] above, or a pharmaceutically acceptable salt thereof, wherein R 7is halogen, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, or a compound of the formula: -S(=O)(=NR N )-R S1 . [6'] The compound as described in any one of [1'] to [3'] above, or a pharmaceutically acceptable salt thereof, wherein L 3 For a single key. [7'] The compound as described in [6'] above, or a pharmaceutically acceptable salt thereof, wherein R 7 It is a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted non-aromatic heterocyclic group. [8'] The compound or pharmaceutically acceptable salt thereof as described in the above [1'] is selected from the group consisting of compounds I-6, I-13, I-14, I-20, I-33, I-46, I-58, I-61, I-66, I-79, I-126, I-130, I-133, I-137 and I-142. [8'-1] The compound or pharmaceutically acceptable salt thereof as described in the above-mentioned [1′] is selected from the group consisting of compounds I-123, I-124, I-136, I-139, I-141, I-143, I-145 and I-147. [8'-2] The compound or pharmaceutically acceptable salt thereof as described in the above-mentioned [1′] is selected from the group consisting of compounds I-151 and I-153. [9'] A pharmaceutical composition comprising the compound described in any one of [1'] to [8'] or [8'-1] to [8'-2] above or a pharmaceutically acceptable salt thereof. [10'] The pharmaceutical composition as described in the aforementioned [9'] has a MGAT2 inhibitory effect. [11'] The pharmaceutical composition as described in [9'] or [10'] above is used for treating or preventing a disease associated with MGAT2. [12'] The pharmaceutical composition as described in the above-mentioned [11′] is used for the treatment or prevention of obesity, metabolic syndrome, hyperlipidemia, high-grade lipidemia, hyperVLDLemia, hyperfatty acidemia, diabetes or arteriosclerosis. [13'] A method for treating or preventing a disease associated with MGAT2, comprising delivering the compound described in any one of [1'] to [8'] or [8'-1] to [8'-2] above, or a pharmaceutically acceptable salt thereof. [14'] A compound as described in any one of [1'] to [8'] or [8'-1] to [8'-2], or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a disease associated with MGAT2. [15'] A use of the compound described in any one of [1'] to [8'] or [8'-1] to [8'-2], or a pharmaceutically acceptable salt thereof, for treating or preventing a disease associated with MGAT2. [Effects of the invention]

[0009] The compound of the present invention has MGAT2 inhibitory effect and can be used as a preventive and / or therapeutic agent for obesity, metabolic syndrome, hyperlipidemia, high-grade lipidemia, high VLDLemia, hyperfatty acidemia, diabetes or arteriosclerosis. [Implementation Method]

[0010] The following is an explanation of the meaning of each term used in this specification. Unless otherwise specified, each term has the same meaning when used alone or in combination with other terms. The phrase "consisting of" means that only the constituent conditions are present. The term "including" does not limit the constituent conditions and does not exclude elements not described.

[0011] The "halogen" includes fluorine, chlorine, bromine and iodine atoms, and fluorine and chlorine atoms are particularly preferred.

[0012] The "alkyl" refers to a straight chain or branched hydrocarbon group having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, and even more preferably 1 to 4 carbon atoms. Examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, and n-decyl. Preferred examples of the "alkyl group" include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and n-pentyl. More preferred examples include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.

[0013] The "alkenyl group" means a straight-chain or branched hydrocarbon group having 2 to 15 carbon atoms, preferably 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, and even more preferably 2 to 4 carbon atoms, and having one or more double bonds at any position. Examples thereof include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, isoprenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, and pentadecenyl. Preferred examples of the "alkenyl group" include vinyl, allyl, propenyl, isopropenyl and butenyl.

[0014] "Alkynyl" means a straight chain or branched hydrocarbon group having 2 to 10 carbon atoms, preferably 2 to 8 carbon atoms, more preferably 2 to 6 carbon atoms, and more preferably 2 to 4 carbon atoms, with one or more triple bonds at any position. It may further have a double bond at any position. Examples thereof include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, and the like. Preferred examples of the "alkynyl group" include ethynyl, propynyl, butynyl and pentynyl.

[0015] The "alkylene group" means a linear or branched divalent hydrocarbon group having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, and even more preferably 1 to 4 carbon atoms. Examples thereof include methylene, ethylene, propylene, tetramethylene, pentamethylene, and hexamethylene.

[0016] The "aromatic carbocyclic group" means a monocyclic or bicyclic or more cyclic aromatic hydrocarbon group, and examples thereof include phenyl, naphthyl, anthracenyl, and phenanthryl. A preferred example of the "aromatic carbocyclic group" is a phenyl group.

[0017] The "non-aromatic carbocyclic group" means a monocyclic or bicyclic saturated hydrocarbon group or a cyclic non-aromatic unsaturated hydrocarbon group. The "non-aromatic carbocyclic group" having two or more rings is a group containing a monocyclic or bicyclic non-aromatic carbocyclic group, in which a ring in the above "aromatic carbocyclic group" is condensed. Furthermore, the "non-aromatic carbocyclic group" also includes a bridged group or a spirocyclic group as shown below. The monocyclic non-aromatic carbocyclic group preferably has 3 to 16 carbon atoms, more preferably 3 to 12 carbon atoms, and even more preferably 4 to 8 carbon atoms. Examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclohexadienyl and the like. The non-aromatic carbocyclic group having two or more rings preferably has 8 to 20 carbon atoms, and more preferably has 8 to 16 carbon atoms. Examples thereof include indanyl group, indenyl group, acenaphthyl group, tetrahydronaphthyl group, and fluorenyl group.

[0018] The "aromatic carbocycle" refers to a cyclic aromatic hydrocarbon containing a single ring or two or more rings, and examples thereof include a benzene ring, a naphthalene ring, an anthracene ring, and a phenanthrene ring. One aspect of the "aromatic carbon ring" includes a benzene ring and a naphthalene ring. Another aspect includes a benzene ring. "Non-aromatic carbocycle" means a cyclic saturated hydrocarbon or a cyclic non-aromatic unsaturated hydrocarbon containing a single ring or two or more rings. "Non-aromatic carbocycle" containing two or more rings also includes a single ring or two or more non-aromatic carbocycle condensed with a ring in the above "aromatic carbocycle". Furthermore, the "non-aromatic carbocyclic ring" also includes a bridged ring or a spiro ring as described below. The monocyclic non-aromatic carbocyclic ring preferably has 3 to 16 carbon atoms, more preferably 3 to 12 carbon atoms, and even more preferably 3 to 8 carbon atoms. Examples thereof include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, and cyclohexadiene. The non-aromatic carbon ring having two or more rings preferably has 8 to 20 carbon atoms, and more preferably has 8 to 16 carbon atoms. Examples thereof include indane, indene, acenaphthene, tetralin, and fluorene.

[0019] The "aromatic heterocyclic group" means a monocyclic or bicyclic aromatic cyclic group having one or more heteroatoms arbitrarily selected from O, S and N, which are the same or different. The bicyclic aromatic heterocyclic group also includes a monocyclic or bicyclic aromatic heterocyclic group in which a ring in the above-mentioned "aromatic carbocyclic group" is condensed. The monocyclic aromatic heterocyclic group is preferably 5-8-membered, more preferably 5-membered or 6-membered. Examples thereof include pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, furanyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, and thiadiazolyl. The aromatic heterocyclic group of two rings is preferably 8-10-membered, more preferably 9-membered or 10-membered. Examples thereof include indolyl, isoindolyl, indazolyl, indolizinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuranyl, isobenzofuranyl, benzothienyl, benzotriazolyl, imidazopyridinyl, triazolopyridinyl, imidazothiazolyl, pyrazinopyridazinyl, oxazolopyridinyl, and thiazolopyridinyl. Examples of the aromatic heterocyclic group having three or more rings include a carbazolyl group, an acridinyl group, a xanthenyl group, a phenothiazinyl group, a phenoxathiyl group, a phenoxazinyl group, and a dibenzofuranyl group.

[0020] The "non-aromatic heterocyclic group" means a monocyclic or bicyclic non-aromatic cyclic group having one or more heteroatoms selected from O, S and N, which are the same or different. The bicyclic non-aromatic heterocyclic group includes a monocyclic or bicyclic non-aromatic heterocyclic group condensed with each ring of the above-mentioned "aromatic carbocyclic group", "non-aromatic carbocyclic group" and / or "aromatic heterocyclic group", and further includes a monocyclic or bicyclic non-aromatic carbocyclic group condensed with a ring of the above-mentioned "aromatic heterocyclic group". Furthermore, the "non-aromatic heterocyclic group" also includes a bridged ring or a spiro ring as described below. The monocyclic non-aromatic heterocyclic group is preferably 3-8-membered, more preferably 5-membered or 6-membered. Examples thereof include dioxanyl, thiirane, oxiranyl, oxetanyl, oxathiolanyl, azetidinyl, thianyl, tetrahydrothiazolyl, tetrahydropyrrolyl, dihydropyrrolyl, tetrahydroimidazolyl, dihydroimidazolyl, pyrazolidinyl, dihydropyrazolyl, piperidinyl, piperazinyl, morpholinyl, N-morpholinyl, thiomorpholinyl, N-thiomorpholinyl, dihydropyridinyl, tetrahydrothiazolyl, tetra ...pyrrolyl, tetrahydropyrrolyl, tetrahydropyrrolyl, tetrahydropyr 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, 1-Hydroxy-1-nitropropenyl, The non-aromatic heterocyclic group having two or more rings preferably has 8 to 20 members, and more preferably has 8 to 10 members, and examples thereof include indolinyl, isoindolinyl, chromanyl, and isochromanyl.

[0021] The "aromatic heterocycle" means a monocyclic or bicyclic aromatic ring having one or more heteroatoms arbitrarily selected from O, S and N which are the same or different in the ring. The "aromatic heterocycle" having two or more rings also includes a monocyclic or two or more aromatic heterocycles in which a ring in the above-mentioned "aromatic carbocycle" is condensed. The monocyclic aromatic heterocycle is preferably 5- to 8-membered, more preferably 5- or 6-membered, and includes, for example, pyrrole, imidazole, pyrazole, pyridine, pyridazine, pyrimidine, pyrazine, triazole, triazine, tetrazole, furan, thiophene, isoxazole, oxazole, oxadiazole, isothiazole, thiazole, and thiadiazole. The bicyclic aromatic heterocyclic ring is preferably 8- to 10-membered, more preferably 9- or 10-membered. Examples thereof include indole, isoindole, indazole, indolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, 1,5-naphthyridine, quinoxaline, purine, pteridine, benzimidazole, benzisoxazole, benzoxazole, benzoxadiazole, benzisothiazole, benzothiazole, benzothiadiazole, benzofuran, isobenzofuran, benzothiophene, benzotriazole, imidazopyridine, triazolopyridine, imidazothiazole, pyrazinopyridazine, oxazolopyridine, and thiazolopyridine. The aromatic heterocyclic ring having three or more rings preferably has 11 to 26 members, and more preferably has 13 or 14 members. Examples thereof include carbazole, acridine, dibenzopyran, phenothiazine, phenoxathiazine, phenoxazine, and dibenzofuran. The "non-aromatic heterocycle" means a monocyclic or bicyclic non-aromatic ring having one or more heteroatoms selected arbitrarily from oxygen atoms, sulfur atoms and nitrogen atoms, which may be the same or different, in the ring. The "non-aromatic heterocycle" having two or more rings also includes a monocyclic or two or more non-aromatic heterocycle in which each of the above-mentioned "aromatic carbocycle", "non-aromatic carbocycle" and / or "aromatic heterocycle" is condensed. Furthermore, the "non-aromatic heterocycle" also includes a bridged ring or a spiro ring as described below. The monocyclic non-aromatic heterocycle is preferably 3-8-membered, more preferably 5-membered or 6-membered. Examples thereof include dioxane, thiirane, oxirane, oxetane, oxathiane, azetidine, thiolane, tetrahydrothiazolidine, tetrahydropyrrole, dihydropyrrole, imidazolidine, dihydroimidazole, pyrazolidine, pyrazoline, piperidine, piperazine, morpholine, thiomorpholine, dihydropyridine, tetrahydropyridine, tetrahydrofuran, tetrahydropyran, dihydrothiazolidine, tetrahydrothiazolidine, tetrahydroisothiazole, dihydrooxazine, hexahydroazacyclopine, tetrahydrodiazacyclopine, tetrahydropyridazine, hexahydropyrimidine, dioxolane, dioxazine, aziridine, dioxolane, oxepan, thiolene, thiin, thiazine, and the like. The non-aromatic heterocyclic ring having two or more rings preferably has 8 to 20 members, and more preferably has 8 to 10 members. Examples thereof include indoline, isoindoline, dihydrochromene, and isohydrochromene.

[0022] The substituents of "substituted carbamoyl", "substituted thiocarbamoyl", "substituted amidino", "substituted amino", "substituted ureido", "substituted guanidino", "substituted aminosulfonyl", "substituted alkyl", "substituted alkenyl", "substituted alkynyl", "substituted alkylene", "substituted alkyloxy", "substituted alkenyloxy", "substituted alkylcarbonyloxy", "substituted alkenylcarbonyloxy", "substituted alkylcarbonyl", "substituted alkenylcarbonyl", "substituted alkyloxycarbonyl", "substituted alkenyloxycarbonyl", "substituted alkylthio", "substituted alkenylthio", "substituted alkylsulfinyl", "substituted alkenylsulfinyl", "substituted alkylsulfonyl", and "substituted alkenylsulfonyl" include the following substituents. The carbon atom or nitrogen atom at any position may be bonded to one or more groups selected from the following substituents. Substituents: halogen, hydroxy, cyano, formyl, formyloxy, thioformyl, carboxyl, thiocarboxyl, dithiocarboxyl, carbamoyl, thiocarbamoyl, amidino, amino, hydroxyamino, hydroxyimino, azido, hydrazine, urea, guanidino, pentafluorosulfenyl, thiol, sulfinyl, sulfonyl, aminosulfonyl, trialkylsilyl, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, alkyloxy, alkenyloxy, alkynyloxy, haloalkyloxy, haloalkyloxyalkyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylthio, alkenylthio, alkynylthio, alkylsulfinyl, alkenylsulfinyl, Alkynylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, monoalkylaminosulfonyl, monoalkenylaminosulfonyl, monoalkynylaminosulfonyl, dialkylaminosulfonyl, dienylaminosulfonyl, dienylaminosulfonyl, monoalkylamino, monoalkenylamino, monoalkynylamino, dialkylamino, dienylamino, dienylamino, monoalkylcarbonylamino, monoalkenylcarbonylamino, monoalkynylcarbonylamino, dialkylcarbonylamino, dienylcarbonylamino, dienylcarbonylamino, monoalkyloxycarbonylamino, monoalkenyloxycarbonylamino, monoalkynyloxycarbonylamino, dialkyloxycarbonylamino, dienyloxycarbonylamino, dienyloxycarbonylamino, monoalkylsulfonylamino, monoalkenylsulfonylamino, monoalkynylsulfonylamino, Dialkylsulfonylamino, dienylsulfonylamino, dialkynylsulfonylamino, monoalkylcarbamoyl, monoalkenylcarbamoyl, monoalkynylcarbamoyl, dialkylcarbamoyl, dienylcarbamoyl, dialkynylcarbamoyl, monoalkyloxycarbamoyl, monoalkenyloxycarbamoyl, monoalkynyloxycarbamoyl, dialkyloxycarbamoyl, dienyloxycarbamoyl, dialkynyloxycarbamoyl, monoalkylcarbonylcarbamoyl, monoalkenylcarbonylcarbamoyl, monoalkynylcarbonylcarbamoyl, monoalkyloxycarbonylcarbamoyl, monoalkenyloxycarbonylcarbamoyl, monoalkynyloxycarbonylcarbamoyl, monoalkylsulfonylcarbamoyl, monoalkenylsulfonylcarbamoyl, monoalkynylsulfonylamino a monoalkylaminosulfonyl group, a monoalkylaminosulfonyl group, a monoalkenylaminosulfonyl group, a monoalkynylaminosulfonyl group, a dialkylaminosulfonyl group, a dienylaminosulfonyl group, a dienylaminosulfonyl group, a monoalkyloxyaminosulfonyl group, a monoalkenyloxyaminosulfonyl group, a monoalkynyloxyaminosulfonyl group, a dialkyloxyaminosulfonyl group, a dienyloxyaminosulfonyl group, a dienyloxyaminosulfonyl group, a monoalkylcarbonylaminosulfonyl group, a monoalkenylcarbonylaminosulfonyl group, a monoalkynylcarbonylaminosulfonyl group, a monoalkyloxycarbonylaminosulfonyl group, a monoalkenyloxycarbonylaminosulfonyl group, a monoalkynyloxycarbonylaminosulfonyl group, a monoalkylsulfonylaminosulfonyl group, a monoalkenylsulfonylaminosulfonyl group, a monoalkynylsulfonylaminosulfonyl group, an aromatic carbocyclic group which may be substituted with a substituent group A,non-aromatic carbocyclic group which may be substituted by substituent group A, aromatic heterocyclic group which may be substituted by substituent group A, non-aromatic heterocyclic group which may be substituted by substituent group A, aromatic carbocyclic oxy group which may be substituted by substituent group A, non-aromatic carbocyclic oxy group which may be substituted by substituent group A, aromatic heterocyclic oxy group which may be substituted by substituent group A, non-aromatic heterocyclic oxy group which may be substituted by substituent group A, aromatic carbocyclic carbonyloxy group which may be substituted by substituent group A, non-aromatic carbocyclic carbonyloxy group which may be substituted by substituent group A, aromatic heterocyclic carbonyloxy group which may be substituted by substituent group A, non-aromatic heterocyclic carbonyloxy group which may be substituted by substituent group A, aromatic carbocyclic carbonyl group which may be substituted by substituent group A, non-aromatic carbocyclic carbonyl group which may be substituted by substituent group A, Aromatic heterocyclic carbonyl substituted by substituent group A, non-aromatic heterocyclic carbonyl substituted by substituent group A, aromatic carbocyclic oxycarbonyl substituted by substituent group A, non-aromatic carbocyclic oxycarbonyl substituted by substituent group A, aromatic heterocyclic oxycarbonyl substituted by substituent group A, non-aromatic heterocyclic oxycarbonyl substituted by substituent group A, aromatic carbocyclic thio substituted by substituent group A, non-aromatic carbocyclic thio substituted by substituent group A, aromatic heterocyclic thio substituted by substituent group A, non-aromatic heterocyclic thio substituted by substituent group A, aromatic carbocyclic sulfinyl substituted by substituent group A, non-aromatic carbocyclic sulfinyl substituted by substituent group A, aromatic heterocyclic sulfinyl substituted by substituent group A , non-aromatic heterocyclic sulfinyl group which may be substituted by substituent group A, aromatic carbocyclic sulfonyl group which may be substituted by substituent group A, non-aromatic carbocyclic sulfonyl group which may be substituted by substituent group A, aromatic heterocyclic sulfonyl group which may be substituted by substituent group A, non-aromatic heterocyclic sulfonyl group which may be substituted by substituent group A, aromatic carbocyclic alkyl group which may be substituted by substituent group A, non-aromatic carbocyclic alkyl group which may be substituted by substituent group A, aromatic heterocyclic alkyl group which may be substituted by substituent group A, non-aromatic heterocyclic alkyl group which may be substituted by substituent group A, aromatic carbocyclic alkyloxy group which may be substituted by substituent group A, non-aromatic carbocyclic alkyloxy group which may be substituted by substituent group A, aromatic heterocyclic alkyloxy group which may be substituted by substituent group A, non-aromatic heterocyclic alkyl group which may be substituted by substituent group A cycloalkyloxy, aromatic carbocyclic alkylcarbonyl which may be substituted by substituent group A, non-aromatic carbocyclic alkylcarbonyl which may be substituted by substituent group A, aromatic heterocyclic alkylcarbonyl which may be substituted by substituent group A, non-aromatic heterocyclic alkylcarbonyl which may be substituted by substituent group A, aromatic carbocyclic alkyloxycarbonyl which may be substituted by substituent group A, non-aromatic carbocyclic alkyloxycarbonyl, aromatic heterocyclic alkyloxycarbonyl which may be substituted by substituent group A, non-aromatic heterocyclic alkyloxycarbonyl which may be substituted by substituent group A, aromatic carbocyclic alkylthio which may be substituted by substituent group A, non-aromatic carbocyclic alkylthio which may be substituted by substituent group A, aromatic heterocyclic alkylthio which may be substituted by substituent group A, non-aromatic heterocyclic alkylthio which may be substituted by substituent group A,Aromatic carbocyclic alkylsulfinyl group which may be substituted by substituent group A, non-aromatic carbocyclic alkylsulfinyl group which may be substituted by substituent group A, aromatic heterocyclic alkylsulfinyl group which may be substituted by substituent group A, non-aromatic heterocyclic alkylsulfinyl group which may be substituted by substituent group A, aromatic carbocyclic alkylsulfonyl group which may be substituted by substituent group A, non-aromatic carbocyclic alkylsulfonyl group which may be substituted by substituent group A, aromatic heterocyclic alkylsulfonyl group which may be substituted by substituent group A, non-aromatic heterocyclic alkylsulfonyl group which may be substituted by substituent group A, aromatic carbocyclic alkylamino group which may be substituted by substituent group A, non-aromatic carbocyclic alkylamino group which may be substituted by substituent group A, aromatic heterocyclic alkylamino group which may be substituted by substituent group A, non-aromatic heterocyclic alkylamino group which may be substituted by substituent group A, aromatic carbocyclic alkylcarbonylamino group which may be substituted by substituent group A, non-aromatic carbocyclic alkylcarbonylamino group which may be substituted by substituent group A, aromatic a non-aromatic heterocycloalkylcarbonylamino group which may be substituted with a substituent group A, an aromatic carbocyclic alkyloxycarbonylamino group which may be substituted with a substituent group A, a non-aromatic carbocyclic alkyloxycarbonylamino group which may be substituted with a substituent group A, an aromatic heterocyclic alkyloxycarbonylamino group which may be substituted with a substituent group A, a non-aromatic heterocyclic alkyloxycarbonylamino group which may be substituted with a substituent group A, an aromatic carbocyclic alkylsulfonylamino group which may be substituted with a substituent group A, a non-aromatic carbocyclic alkylsulfonylamino group which may be substituted with a substituent group A, an aromatic heterocyclic alkylsulfonylamino group which may be substituted with a substituent group A, a non-aromatic heterocyclic alkylsulfonylamino group which may be substituted with a substituent group A, an aromatic carbocyclic alkyloxy group which may be substituted with a substituent group A, a non-aromatic carbocyclic alkyloxy group which may be substituted with a substituent group A, an aromatic heterocyclic alkyloxy group which may be substituted with a substituent group A, and a non-aromatic heterocyclic alkyloxy group which may be substituted with a substituent group A. “Substituent group A may be substituted” means that a carbon atom, a nitrogen atom or a sulfur atom at any position may be bonded to one or more groups selected from substituent group A. Substituent group A: oxo, halogen, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkyloxy, haloalkyloxy, alkyloxycarbonylalkyl, monoalkylamino, dialkylamino, aromatic carbocyclic group, aromatic heterocyclic group, and aromatic carbocyclic group. The same applies to the following “may be substituted by substituent group B”. Substituent group B: halogen, alkyl, and haloalkyl.

[0023] "substituted non-aromatic carbocycle", "substituted non-aromatic heterocycle", "substituted aromatic carbocyclyl", "substituted non-aromatic carbocyclyl", "substituted aromatic heterocyclyl", "substituted non-aromatic heterocyclyl", "substituted aromatic carbocyclyloxy", "substituted non-aromatic carbocyclyloxy", "substituted aromatic heterocyclyloxy", "substituted non-aromatic heterocyclyloxy", "substituted aromatic carbocyclylcarbonyloxy", "substituted non-aromatic carbocyclylcarbonyloxy", "substituted aromatic heterocyclylcarbonyloxy", "substituted non-aromatic heterocyclylcarbonyloxy", "substituted aromatic carbocyclylcarbonyl", "substituted non-aromatic carbocyclylcarbonyl", "substituted aromatic heterocyclylcarbonyl", "substituted non-aromatic heterocyclylcarbonyl", "substituted aromatic carbocyclyloxycarbonyl", "substituted non-aromatic The substituents on the rings of the “aromatic carbocycle”, “non-aromatic carbocycle”, “aromatic heterocycle” and “non-aromatic heterocycle” include the following substituents: “substituted carbocycle oxycarbonyl”, “substituted aromatic heterocycle oxycarbonyl”, “substituted non-aromatic heterocycle oxycarbonyl”, “substituted aromatic carbocycle thio”, “substituted non-aromatic carbocycle thio”, “substituted aromatic heterocycle thio”, “substituted non-aromatic heterocycle thio”, “substituted aromatic carbocycle sulfinyl”, “substituted non-aromatic carbocycle sulfinyl”, “substituted aromatic heterocycle sulfinyl”, “substituted non-aromatic heterocycle sulfinyl”, “substituted aromatic carbocycle sulfonyl”, “substituted non-aromatic carbocycle sulfonyl”, “substituted aromatic heterocycle sulfonyl” and “substituted non-aromatic heterocycle sulfonyl”. The following substituents can be mentioned as the ring substituents. The atom at any position on the ring may be bonded to one or more groups selected from the following substituents. Substituents: oxo, halogen, hydroxy, cyano, formyl, formyloxy, thioformyl, carboxyl, thiocarboxyl, dithiocarboxyl, carbamoyl, thiocarbamoyl, amidino, amino, hydroxyamino, imino, hydroxyimino, azido, hydrazine, urea, guanidino, pentafluorosulfenyl, thiol, sulfinyl, sulfonic acid, aminosulfonyl, trialkylsilyl, alkyl, alkenyl, alkynyl, haloalkyl, alkyloxy, alkenyloxy, alkynyloxy, haloalkyloxy, haloalkenyloxy, haloalkynyloxy, alkyloxyalkyloxy, haloalkyloxyalkyloxy, hydroxyalkyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl , alkylthio, alkenylthio, alkynylthio, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, monoalkylaminosulfonyl, monoalkenylaminosulfonyl, monoalkynylaminosulfonyl, dialkylaminosulfonyl, dienylaminosulfonyl, dialkynylaminosulfonyl, monoalkylamino, monoalkenylamino, monoalkynylamino, monohaloalkylamino, dialkylamino, dienylamino, dialkynylamino, monoalkylcarbonylamino, monoalkenylcarbonylamino, monoalkynylcarbonylamino, monohaloalkylcarbonylamino, dialkylcarbonylamino, dienylcarbonylamino, dialkynylcarbonylamino, monoalkyloxycarbonylamino, monoalkenyloxycarbonylamino, monoalkynyloxycarbonylamino, dialkyloxycarbonylamino, Dialkenyloxycarbonylamino, dialkynyloxycarbonylamino, monoalkylsulfonylamino, monoalkenylsulfonylamino, monoalkynylsulfonylamino, dialkylsulfonylamino, dienylsulfonylamino, dialkynylsulfonylamino, alkylimino, alkenylimino, alkynylimino, alkyloxyimino, alkenyloxyimino, alkynyloxyimino, monoalkylcarbamoyl, monoalkenylcarbamoyl, monoalkynylcarbamoyl, dialkylcarbamoyl, dienylcarbamoyl, dialkynylcarbamoyl, monoalkyloxycarbamoyl, monoalkenyloxycarbamoyl, monoalkynyloxycarbamoyl, dialkyloxycarbamoyl, dienyloxycarbamoyl, dialkynyloxycarbamoyl, monoalkylcarbonylcarbamoyl, mono alkenylcarbonylcarbamoyl, monoalkynylcarbonylcarbamoyl, monoalkyloxycarbonylcarbamoyl, monoalkenyloxycarbonylcarbamoyl, monoalkynyloxycarbonylcarbamoyl, monoalkylsulfonylcarbamoyl, monoalkenylsulfonylcarbamoyl, monoalkynylsulfonylcarbamoyl, monoalkylaminosulfonyl, monoalkenylaminosulfonyl, monoalkynylaminosulfonyl, dialkylaminosulfonyl, dienylaminosulfonyl, diealkynylaminosulfonyl, monoalkyloxyaminosulfonyl, monoalkenyloxyaminosulfonyl, monoalkynyloxyaminosulfonyl, dialkyloxyaminosulfonyl, dienyloxyaminosulfonyl, dialkynyloxyaminosulfonyl, monoalkylcarbonylaminosulfonyl, monoalkenylcarbonylaminosulfonyl, monoalkynylcarbonylaminosulfonyl,monoalkyloxycarbonylaminosulfonyl, monoalkenyloxycarbonylaminosulfonyl, monoalkynyloxycarbonylaminosulfonyl, monoalkylsulfonylaminosulfonyl, monoalkenylsulfonylaminosulfonyl, monoalkynylsulfonylaminosulfonyl, aromatic carbocyclic group which may be substituted by substituent group A, non-aromatic carbocyclic group which may be substituted by substituent group A, aromatic heterocyclic group which may be substituted by substituent group A, non-aromatic heterocyclic group which may be substituted by substituent group A, aromatic carbocyclic oxy group which may be substituted by substituent group A, non-aromatic carbocyclic oxy group which may be substituted by substituent group A, aromatic heterocyclic oxy group which may be substituted by substituent group A, non-aromatic heterocyclic oxy group which may be substituted by substituent group A, aromatic carbocyclic carbonyl oxy group which may be substituted by substituent group A, A non-aromatic carbocyclic carbonyloxy substituted by A, an aromatic heterocyclic carbonyloxy group which may be substituted by a substituent group A, a non-aromatic heterocyclic carbonyloxy group which may be substituted by a substituent group A, an aromatic carbocyclic carbonyl group which may be substituted by a substituent group A, a non-aromatic carbocyclic carbonyl group which may be substituted by a substituent group A, an aromatic heterocyclic carbonyl group which may be substituted by a substituent group A, a non-aromatic heterocyclic carbonyl group which may be substituted by a substituent group A, an aromatic carbocyclic oxycarbonyl group which may be substituted by a substituent group A, a non-aromatic carbocyclic oxycarbonyl group which may be substituted by a substituent group A, an aromatic heterocyclic oxycarbonyl group which may be substituted by a substituent group A, a non-aromatic heterocyclic oxycarbonyl group which may be substituted by a substituent group A, an aromatic carbocyclic thio group which may be substituted by a substituent group A, a non-aromatic carbocyclic thio, an aromatic heterocyclic thio group which may be substituted by a substituent group A, a non-aromatic heterocyclic thio group which may be substituted by a substituent group A, an aromatic carbocyclic sulfinyl group which may be substituted by a substituent group A, a non-aromatic carbocyclic sulfinyl group which may be substituted by a substituent group A, an aromatic heterocyclic sulfinyl group which may be substituted by a substituent group A, a non-aromatic heterocyclic sulfinyl group which may be substituted by a substituent group A, an aromatic carbocyclic sulfonyl group which may be substituted by a substituent group A, a non-aromatic carbocyclic sulfonyl group which may be substituted by a substituent group A, an aromatic heterocyclic sulfonyl group which may be substituted by a substituent group A, a non-aromatic heterocyclic sulfonyl group which may be substituted by a substituent group A, an aromatic carbocyclic amino group which may be substituted by a substituent group A, a non-aromatic carbocyclic amino group which may be substituted by a substituent group A substituted aromatic heterocyclic amino group, non-aromatic heterocyclic amino group which may be substituted by substituent group A, aromatic carbocyclic alkyl group which may be substituted by substituent group A, non-aromatic carbocyclic alkyl group which may be substituted by substituent group A, aromatic heterocyclic alkyl group which may be substituted by substituent group A, non-aromatic heterocyclic alkyl group which may be substituted by substituent group A, aromatic carbocyclic alkyloxy group which may be substituted by substituent group A, non-aromatic carbocyclic alkyloxy group which may be substituted by substituent group A, aromatic heterocyclic alkyloxy group which may be substituted by substituent group A, non-aromatic heterocyclic alkyloxy group which may be substituted by substituent group A, aromatic carbocyclic alkylcarbonyl group which may be substituted by substituent group A, non-aromatic carbocyclic alkylcarbonyl group which may be substituted by substituent group A, aromatic heterocyclic alkylcarbonyl group which may be substituted by substituent group A,non-aromatic heterocycloalkylcarbonyl substituted with substituent group A, aromatic carbocycloalkyloxycarbonyl substituted with substituent group A, non-aromatic carbocycloalkyloxycarbonyl substituted with substituent group A, aromatic heterocycloalkyloxycarbonyl substituted with substituent group A, non-aromatic heterocycloalkyloxycarbonyl substituted with substituent group A, aromatic carbocycloalkylthio substituted with substituent group A, non-aromatic carbocycloalkylthio substituted with substituent group A, aromatic heterocycloalkylthio substituted with substituent group A, non-aromatic heterocycloalkylthio substituted with substituent group A, aromatic carbocyclic alkylsulfinyl, non-aromatic carbocyclic alkylsulfinyl which may be substituted with substituent group A, aromatic heterocyclic alkylsulfinyl which may be substituted with substituent group A, non-aromatic heterocyclic alkylsulfinyl which may be substituted with substituent group A, aromatic carbocyclic alkylsulfonyl which may be substituted with substituent group A, non-aromatic carbocyclic alkylsulfonyl which may be substituted with substituent group A, aromatic heterocyclic alkylsulfonyl which may be substituted with substituent group A, non-aromatic heterocyclic alkylsulfonyl which may be substituted with substituent group A, aromatic carbocyclic alkylamino which may be substituted with substituent group A, Aromatic heterocycloalkylamino substituted by substituent group A, non-aromatic heterocycloalkylamino substituted by substituent group A, aromatic carbocyclic alkylcarbonylamino substituted by substituent group A, non-aromatic carbocyclic alkylcarbonylamino substituted by substituent group A, aromatic heterocycloalkylcarbonylamino substituted by substituent group A, non-aromatic heterocycloalkylcarbonylamino substituted by substituent group A, aromatic carbocyclic alkyloxycarbonylamino substituted by substituent group A, non-aromatic carbocyclic alkyloxycarbonylamino substituted by substituent group A, aromatic heterocycloalkyloxycarbonylamino substituted by substituent group A, Non-aromatic heterocycloalkyloxycarbonylamino substituted with group A, aromatic carbocycloalkylsulfonylamino substituted with group A, non-aromatic carbocycloalkylsulfonylamino substituted with group A, aromatic heterocycloalkylsulfonylamino substituted with group A, non-aromatic heterocycloalkylsulfonylamino substituted with group A, aromatic carbocyclic oxyalkylamino substituted with group A, non-aromatic carbocyclic oxyalkylamino substituted with group A, aromatic heterocyclic oxyalkylamino substituted with group A, and non-aromatic heterocyclic oxyalkylamino substituted with group A.

[0024] Aspects and preferred aspects of each substituent in the compound represented by formula (I) are shown below. Preferred are compounds in which possible combinations of each aspect of each substituent are shown below.

[0025] R 1Examples thereof include hydrogen, hydroxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted a substituted aromatic heterocyclic carbonyl group, a substituted or unsubstituted non-aromatic heterocyclic carbonyl group, a substituted or unsubstituted aromatic carbocyclic oxycarbonyl group, a substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl group, a substituted or unsubstituted aromatic heterocyclic oxycarbonyl group, a substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl group, a substituted or unsubstituted aromatic carbocyclic sulfonyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, a substituted or unsubstituted aromatic heterocyclic sulfonyl group, or a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group. R 1 Preferred aspects include hydrogen and hydroxy. R 1 A more preferred aspect of is hydrogen. R 1 When substituted, examples of the substituent include halogen, hydroxyl, amino, alkyl, monoalkylamino, dialkylamino, aromatic carbocyclic group, non-aromatic carbocyclic group, aromatic heterocyclic group, or non-aromatic heterocyclic group.

[0026] R 2a and R 2b A preferred aspect is one that forms ring B together with the adjacent carbon atom. R 2a and R 2b Other aspects of are preferably the following aspects, R 2a As shown in the following formula: R 2b is hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted alkylsulfonyl. R 2b More preferred aspects are hydrogen or substituted or unsubstituted alkyl. R 2b Particularly preferred are substituted or unsubstituted alkyl groups, with alkyl groups and haloalkyl groups being particularly preferred. In addition, R 2b When the moiety is substituted, examples of the substituent include halogen.

[0027] Examples of ring B include a substituted or unsubstituted non-aromatic carbocyclic ring, or a substituted or unsubstituted non-aromatic heterocyclic ring. Preferred aspects of ring B include those represented by the following formula: More preferred aspects of ring B include those represented by the following formula: Particularly preferred aspects of ring B include those represented by the following formula: Other preferred aspects of ring B include those represented by the following formula: More preferably, the following formula can be mentioned: Other preferred aspects of ring B include those represented by the following formula: More preferably, the following formula can be mentioned: Particularly preferred are those represented by the following formula: Other preferred aspects of ring B include those represented by the following formula: More preferably, the following formula can be mentioned: Other preferred aspects of ring B include those represented by the following formula: More preferably, the following formula can be mentioned:

[0028] Other aspects of ring B include those represented by the following formula:

[0029] Examples of ring D include an aromatic carbocyclic ring, a non-aromatic carbocyclic ring, an aromatic heterocyclic ring, and a non-aromatic heterocyclic ring. Preferred examples of ring D include aromatic carbocyclic rings.

[0030] B 1 CR can be listed 11a R 11b NR 11c , O, or S. B 1 Preferred aspects include CR 11a R 11b . B1 A more preferred aspect of is C.

[0031] B 2 CR can be listed 12a R 12b NR 12c , O, or S. B 2 Preferred aspects include CR 12a R 12b . B 2 A more preferred aspect of is C.

[0032] B 3 CR can be listed 13a R 13b NR 13c , O, or S. B 3 Preferred aspects include CR 13a R 13b , or O. B 3 Preferred specific aspects of include, for example, CH2, or O.

[0033] B 4 CR can be listed 14a R 14b NR 14c , O, or S. B 4 Preferred aspects include CR 14a R 14b . B 4 Preferred specific aspects include CH2 or CF2.

[0034] B 5 CR can be listed 15a R 15b NR 15c , O, or S. B 5 Preferred aspects include CR 15a R 15b . B 5 A preferred specific aspect of CH2 is mentioned.

[0035] However, -B 1 -B 2 -B 3 -B 4 -or-B 1 -B 2 -B 3 -B 4 -B 5- It is not the case that three or more atoms of any one of N, O, and S are continuously bonded, such as in -OOOO- or -SSSS-.

[0036] R 11a , R 12a , R 13a , R 14a , and R 15a The substituted or unsubstituted amino group may be exemplified as follows: each independently being: hydrogen, halogen, hydroxyl, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted substituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl , substituted or unsubstituted aromatic carbocyclic sulfenyl, substituted or unsubstituted non-aromatic carbocyclic sulfenyl, substituted or unsubstituted aromatic heterocyclic sulfenyl, substituted or unsubstituted non-aromatic heterocyclic sulfenyl, substituted or unsubstituted aromatic carbocyclic sulfinyl, substituted or unsubstituted non-aromatic carbocyclic sulfinyl, substituted or unsubstituted aromatic heterocyclic sulfinyl, substituted or unsubstituted non-aromatic heterocyclic sulfinyl, substituted or unsubstituted aromatic carbocyclic sulfonyl, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, substituted or unsubstituted aromatic heterocyclic sulfonyl, substituted or unsubstituted non-aromatic heterocyclic sulfonyl, formula: -LN=S(=O)(-RS1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NR N )2-R S1 Base shown. Here, the formula: -LN=S(=O)(-R S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , formula: -S(=NR N )2-R S1 The groups shown are groups each having the following chemical structure. R 11a , R 12a , R 13a , R 14a , and R 15a Preferred aspects of the invention include each independently being hydrogen, halogen, or substituted or unsubstituted alkyl. R 11a , R 12a , R 13a , R 14a , and R 15a More preferred aspects include hydrogen and halogen. R 11a , R 12a , R 13a , R 14a , and R 15a When substituted, the substituents are each independently halogen, hydroxy, amino, alkyl, monoalkylamino, dialkylamino, aromatic carbocyclic group, non-aromatic carbocyclic group, aromatic heterocyclic group, or non-aromatic heterocyclic group.

[0037] R 11b , R 12b , R 13b , R 14b , and R 15bThe substituted or unsubstituted amino group may be exemplified as follows: each independently being: hydrogen, halogen, hydroxyl, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted substituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl , substituted or unsubstituted aromatic carbocyclic sulfenyl, substituted or unsubstituted non-aromatic carbocyclic sulfenyl, substituted or unsubstituted aromatic heterocyclic sulfenyl, substituted or unsubstituted non-aromatic heterocyclic sulfenyl, substituted or unsubstituted aromatic carbocyclic sulfinyl, substituted or unsubstituted non-aromatic carbocyclic sulfinyl, substituted or unsubstituted aromatic heterocyclic sulfinyl, substituted or unsubstituted non-aromatic heterocyclic sulfinyl, substituted or unsubstituted aromatic carbocyclic sulfonyl, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, substituted or unsubstituted aromatic heterocyclic sulfonyl, substituted or unsubstituted non-aromatic heterocyclic sulfonyl, formula: -LN=S(=O)(-R S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NRN )2-R S1 Base shown. R 11b , R 12b , R 13b , R 14b , and R 15b Preferred aspects include hydrogen and halogen. R 11b , R 12b , R 13b , R 14b , and R 15b When substituted, the substituents are each independently halogen, hydroxy, amino, alkyl, monoalkylamino, dialkylamino, aromatic carbocyclic group, non-aromatic carbocyclic group, aromatic heterocyclic group, or non-aromatic heterocyclic group.

[0038] R 11c , R 12c , R 13c , R 14c , and R 15cThe substituted or unsubstituted amino group may be exemplified as a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkyloxy group, a substituted or unsubstituted alkenyloxy group, a substituted or unsubstituted alkylcarbonyl group, a substituted or unsubstituted alkenylcarbonyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkylcarbonyl ... oxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic group oxy, substituted or unsubstituted aromatic heterocyclic oxy, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic thio, The invention further comprises a substituted or unsubstituted non-aromatic carbocyclic sulfenyl group, a substituted or unsubstituted aromatic heterocyclic sulfenyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfenyl group, a substituted or unsubstituted aromatic carbocyclic sulfinyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfinyl group, a substituted or unsubstituted aromatic heterocyclic sulfinyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfinyl group, a substituted or unsubstituted aromatic carbocyclic sulfonyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, a substituted or unsubstituted aromatic heterocyclic sulfonyl group, or a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group. R 11c , R 12c , R 13c , R 14c , and R 15c Preferred aspects of the invention include each independently being hydrogen, halogen, or substituted or unsubstituted alkyl. R 11c , R 12c , R 13c , R 14c , and R 15c A more preferred aspect of is hydrogen. R 11c , R 12c , R 13c, R 14c , and R 15c When substituted, the substituents are each independently halogen, hydroxy, amino, alkyl, monoalkylamino, dialkylamino, aromatic carbocyclic group, non-aromatic carbocyclic group, aromatic heterocyclic group, or non-aromatic heterocyclic group.

[0039] R 11a With R 12a , R 12a With R 13a , R 13a With R 14a , and / or R 14a With R 15a can form a substituted or unsubstituted aromatic carbocyclic ring, a substituted or unsubstituted non-aromatic carbocyclic ring, a substituted or unsubstituted aromatic heterocyclic ring, or a substituted or unsubstituted non-aromatic heterocyclic ring together with adjacent carbon atoms, and / or R 11c With R 12a , R 11c With R 12c , R 12c With R 11a , R 12c With R 13a , R 12c With R 13c , R 13c With R 12a , R 13c With R 14a , R 13c With R 14c , R 14c With R 13a , R 14c With R 15a , R 14c With R 15c , and / or R 15c With R 14a can form a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle together with adjacent atoms, and / or R 11a With R 13a , R 11a With R 13c , R 11a With R 14a , R 11a With R 14c , R 11a With R 15a , R 11a With R 15c , R 11c With R 13a , R 11c With R 13c , R 11cWith R 14a , R 11c With R 14c , R 11c With R 15a , R 11c With R 15c , R 12a With R 14a , R 12a With R 14c , R 12a With R 15a , R 12a With R 15c , R 12c With R 14a , R 12c With R 14c , R 12c With R 15a , R 12c With R 15c , R 13a With R 15a , R 13a With R 15c , R 13c With R 15a , and / or R 13c With R 15c is a C2-C4 bridge that can together form an insertable heteroatom, and / or R 11b With R 12b , R 11b With R 12c , R 11c With R 12b , R 11c With R 12c , R 12b With R 13b , R 12b With R 13c , R 12c With R 13b , R 12c With R 13c , R 13b With R 14b , R 13b With R 14c , R 13c With R 14b , R 13c With R 14c , R 14b With R 15b , R 14b With R 15c , R 14c With R 15b , and / or R 14c With R 15c To be able to bond together.

[0040] An integer of 1 to 4 can be mentioned as n. A preferred aspect of n is an integer of 1-3. A more preferred aspect of n is 1 or 2.

[0041] R S1 and R S2 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, or substituted or unsubstituted non-aromatic heterocyclic group, or R bonded to the same sulfur atom S1 and R S2 is a substituted or unsubstituted non-aromatic heterocyclic ring that may be formed together with the sulfur atom. R S1 and R S2 Preferred aspects of the above include those which are each independently hydrogen or a substituted or unsubstituted alkyl group. R S1 and R S2 A more preferred aspect of is hydrogen. R S1 and R S2 When substituted, examples of the substituent include, each independently, halogen, hydroxy, amino, alkyl, alkyloxy, monoalkylamino, dialkylamino, aromatic carbocyclic group, non-aromatic carbocyclic group, aromatic heterocyclic group, or non-aromatic heterocyclic group.

[0042] R N Examples include, each independently, hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, or substituted or unsubstituted non-aromatic heterocyclic carbonyl. R N Preferred aspects of the above include those which are each independently hydrogen or a substituted or unsubstituted alkyl group. R N A more preferred aspect of the invention includes alkyl groups which are each independently substituted or unsubstituted. R N When substituted, examples of the substituent include halogen, hydroxy, amino, alkyl, alkyloxy, monoalkylamino, dialkylamino, aromatic carbocyclic group, non-aromatic carbocyclic group, aromatic heterocyclic group, or non-aromatic heterocyclic group.

[0043] L is each independently a single bond, an alkylene group or C(═O). Preferred aspects of L include those that are each independently a single bond or an alkylene group. A more preferred aspect of L is a single bond.

[0044] An integer of 1 to 5 can be mentioned as m. A preferred aspect of m is an integer of 1-3. A more preferred aspect of m is 1 or 2.

[0045] Examples of ring C include an aromatic carbocyclic ring, an aromatic heterocyclic ring, a non-aromatic carbocyclic ring, and a non-aromatic heterocyclic ring. Preferred examples of ring C include aromatic carbocyclic rings and aromatic heterocyclic rings. More preferred aspects of ring C include benzene, naphthalene, indane, pyridine, pyrimidine, pyrazole, piperidine, piperazine, benzodioxazole, benzothiophene, or thiazole. Still more preferably, ring C includes benzene or pyridine. Particularly preferred embodiment of the ring C is benzene.

[0046] R 5Examples of the group that can be mentioned are each independently halogen, hydroxy, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl , substituted or unsubstituted aromatic carbocyclic sulfenyl, substituted or unsubstituted non-aromatic carbocyclic sulfenyl, substituted or unsubstituted aromatic heterocyclic sulfenyl, substituted or unsubstituted non-aromatic heterocyclic sulfenyl, substituted or unsubstituted aromatic carbocyclic sulfinyl, substituted or unsubstituted non-aromatic carbocyclic sulfinyl, substituted or unsubstituted aromatic heterocyclic sulfinyl, substituted or unsubstituted non-aromatic heterocyclic sulfinyl, substituted or unsubstituted aromatic carbocyclic sulfonyl, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, substituted or unsubstituted aromatic heterocyclic sulfonyl, substituted or unsubstituted non-aromatic heterocyclic sulfonyl, formula: -LN=S(=O)(-R S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NRN )2-R S1 Base shown. R 5 Preferred aspects include, each independently, halogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, or substituted or unsubstituted non-aromatic heterocyclic group. R 5 A more preferred aspect of the invention is that each of them independently is: halogen, cyano, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, or substituted or unsubstituted non-aromatic heterocyclic group. R 5 More preferred aspects include, each independently, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, or substituted or unsubstituted non-aromatic heterocyclic group. R 5 Particularly preferred aspects of include halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted non-aromatic carbocyclic group, or substituted or unsubstituted non-aromatic heterocyclic group. R 5 When substituted, examples of the substituent include halogen, alkyl, haloalkyl, cyanoalkyl, alkyloxyalkyl, haloalkylcarbonyl, non-aromatic carbocyclic group, non-aromatic heterocyclic group, non-aromatic carbocyclic alkyl, aromatic heterocyclic alkyl, and non-aromatic heterocyclic alkyl.

[0047] R 3aExamples thereof include hydrogen, halogen, hydroxyl, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy group, substituted or unsubstituted aromatic carbocyclic sulfonyl group, substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, substituted or unsubstituted aromatic heterocyclic sulfonyl group, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl group. R 3a A preferred aspect of is hydrogen. R 3a When the group is substituted, examples of the substituent include halogen, hydroxyl, amino, alkyl, monoalkylamino, dialkylamino, aromatic carbocyclic group, non-aromatic carbocyclic group, aromatic heterocyclic group, or non-aromatic heterocyclic group.

[0048] R 3b Examples thereof include hydrogen, halogen, hydroxyl, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy group, substituted or unsubstituted aromatic carbocyclic sulfonyl group, substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, substituted or unsubstituted aromatic heterocyclic sulfonyl group, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl group. R 3b A preferred aspect of is hydrogen. R 3b When the group is substituted, examples of the substituent include halogen, hydroxyl, amino, alkyl, monoalkylamino, dialkylamino, aromatic carbocyclic group, non-aromatic carbocyclic group, aromatic heterocyclic group, or non-aromatic heterocyclic group.

[0049] R 4a The following formula can be cited: R 4a More preferred aspects include

[0050] R 4bExamples thereof include halogen, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxy substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfenyl, substituted or unsubstituted non-aromatic carbocyclic sulfenyl, substituted or unsubstituted aromatic heterocyclic sulfenyl, substituted or unsubstituted non-aromatic heterocyclic sulfenyl, substituted or unsubstituted aromatic carbocyclic sulfinyl, substituted or unsubstituted non-aromatic carbocyclic sulfinyl, substituted or unsubstituted aromatic heterocyclic sulfinyl, substituted or unsubstituted non-aromatic heterocyclic sulfinyl, substituted or unsubstituted aromatic carbocyclic sulfonyl, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, substituted or unsubstituted aromatic heterocyclic sulfonyl, substituted or unsubstituted non-aromatic heterocyclic sulfonyl, formula: -LN=S(=O)(-R S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NR N )2-RS1 Base shown. R 4b Preferred aspects include substituted or unsubstituted alkyl groups, substituted or unsubstituted aromatic carbocyclic groups, substituted or unsubstituted non-aromatic carbocyclic groups, substituted or unsubstituted aromatic heterocyclic groups, or substituted or unsubstituted non-aromatic heterocyclic groups. R 4b More preferred aspects include substituted or unsubstituted alkyl groups, substituted or unsubstituted aromatic carbocyclic groups, and substituted or unsubstituted aromatic heterocyclic groups. R 4b Examples of the substituent when substituted include halogen, hydroxyl, cyano, alkyl, alkenyl, haloalkyl, hydroxyalkyl, alkyloxy, haloalkyloxy, alkylsulfonyl, dialkylamino, an aromatic carbocyclic group which may be substituted by a substituent group B, a non-aromatic carbocyclic group which may be substituted by a substituent group B, an aromatic heterocyclic group which may be substituted by a substituent group B, and a non-aromatic heterocyclic group which may be substituted by a substituent group B. R 4b Preferred substituents when substituted include halogen, cyano, alkyl, haloalkyl, hydroxyalkyl, alkyloxy, haloalkyloxy, alkylsulfonyl, an aromatic carbocyclic group which may be substituted with a substituent group B, a non-aromatic carbocyclic group which may be substituted with a substituent group B, an aromatic heterocyclic group which may be substituted with a substituent group B, a non-aromatic heterocyclic group which may be substituted with a substituent group B, an aromatic carbocyclic oxy group which may be substituted with a substituent group B, a non-aromatic carbocyclic oxy group which may be substituted with a substituent group B, an aromatic heterocyclic oxy group which may be substituted with a substituent group B, and a non-aromatic heterocyclic oxy group which may be substituted with a substituent group B.

[0051] L 3 Examples include a single bond and a substituted or unsubstituted alkylene group. L 3 A preferred aspect of is a single bond, an unsubstituted alkylene group, or an alkylene group substituted by a halogen. L 3 Preferred specific aspects of can include a single bond, a methylene group, or those represented by the following formula:

[0052] R 7Examples thereof include hydrogen, halogen, hydroxyl, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl , substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic hetero epoxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic sulfenyl, substituted or unsubstituted non-aromatic carbocyclic sulfenyl, substituted or unsubstituted aromatic heterocyclic sulfenyl, substituted or unsubstituted non-aromatic heterocyclic sulfenyl, substituted or unsubstituted aromatic carbocyclic sulfinyl, substituted or unsubstituted non-aromatic carbocyclic sulfinyl, substituted or unsubstituted aromatic heterocyclic sulfinyl, substituted or unsubstituted non-aromatic heterocyclic sulfinyl, substituted or unsubstituted aromatic carbocyclic sulfonyl, substituted or unsubstituted non-aromatic carbocyclic sulfonyl, substituted or unsubstituted aromatic heterocyclic sulfonyl, substituted or unsubstituted non-aromatic heterocyclic sulfonyl, formula: -N=S(=O)(-R S1 )-R S2 、Formula: -S(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NR N )2-RS1 Base shown. R 7 Preferred aspects of the invention include: halogen, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, formula: -S(=O)(=NR N )-R S1 Base shown. R 7 When the substituent is substituted, examples of the substituent include oxo, halogen, cyano, hydroxy, alkyl, haloalkyl, alkyloxy, haloalkyloxy, hydroxyalkyl, alkylcarbonyl, or alkylsulfonyl.

[0053] R 6The substituted or unsubstituted amino group may be exemplified by halogen, hydroxyl, cyano, carboxyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted substituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyloxy, substituted or unsubstituted non-aromatic carbocyclic carbonyloxy, substituted or unsubstituted aromatic heterocyclic carbonyloxy, substituted or unsubstituted non-aromatic heterocyclic carbonyloxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, a substituted or unsubstituted aromatic carbocyclic sulfide group, a substituted or unsubstituted non-aromatic carbocyclic sulfide group, a substituted or unsubstituted aromatic heterocyclic sulfide group, a substituted or unsubstituted non-aromatic heterocyclic sulfide group, a substituted or unsubstituted aromatic carbocyclic sulfinyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfinyl group, a substituted or unsubstituted aromatic heterocyclic sulfinyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfinyl group, a substituted or unsubstituted aromatic carbocyclic sulfonyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, a substituted or unsubstituted aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted aromatic ... non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfon S1 )-R S2 、Formula: -LS(=O)(=NR N )-R S1 、Formula: -N=S(=NR N )(-R S1 )-R S2 , or formula: -S(=NRN )2-R S1 Base shown. R 6 Preferred aspects of the invention include, each independently, halogen, cyano, hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted non-aromatic heterocyclic oxy group, substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, or substituted or unsubstituted non-aromatic heterocyclic sulfonyl group. R 6 In a more preferred aspect, each independently is: halogen, or substituted or unsubstituted alkyloxy. R 6 A more preferred aspect is that each is independently: halogen, or haloalkyloxy. R 6 Examples of the substituent when substituted include halogen, alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkyloxy, haloalkyloxy, alkyloxyalkyl, haloalkylcarbonyl, alkyloxycarbonylalkyl, an aromatic carbocyclic group which may be substituted with a substituent group B, a non-aromatic carbocyclic group which may be substituted with a substituent group B, an aromatic heterocyclic group which may be substituted with a substituent group B, a non-aromatic heterocyclic group which may be substituted with a substituent group B, an aromatic carbocyclic oxy group which may be substituted with a substituent group B, a non-aromatic carbocyclic oxy group which may be substituted with a substituent group B, an aromatic heterocyclic oxy group which may be substituted with a substituent group B, and a non-aromatic heterocyclic oxy group which may be substituted with a substituent group B.

[0054] R 16Examples thereof include hydrogen, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorosulfenyl, sulfonic acid, substituted or unsubstituted aminosulfonyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, a substituted or unsubstituted alkenyloxycarbonyl group, a substituted or unsubstituted alkylthio group, a substituted or unsubstituted alkenylthio group, a substituted or unsubstituted alkylsulfinyl group, a substituted or unsubstituted alkenylsulfinyl group, a substituted or unsubstituted alkylsulfonyl group, a substituted or unsubstituted alkenylsulfonyl group, a substituted or unsubstituted aromatic carbocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic carbocyclic oxy group, a substituted or unsubstituted non-aromatic carbocyclic oxy group, substituted or unsubstituted aromatic heterocyclic oxy, substituted or unsubstituted non-aromatic heterocyclic oxy, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, substituted or unsubstituted non-aromatic heterocyclic carbonyl, substituted or unsubstituted aromatic carbocyclic oxycarbonyl, substituted or unsubstituted non-aromatic carbocyclic oxycarbonyl, substituted or unsubstituted aromatic heterocyclic oxycarbonyl, substituted or unsubstituted non-aromatic heterocyclic oxycarbonyl, substituted or unsubstituted aromatic carbocyclic thio, substituted or unsubstituted a substituted non-aromatic carbocyclic sulfide group, a substituted or unsubstituted aromatic heterocyclic sulfide group, a substituted or unsubstituted non-aromatic heterocyclic sulfide group, a substituted or unsubstituted aromatic carbocyclic sulfinyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfinyl group, a substituted or unsubstituted aromatic heterocyclic sulfinyl group, a substituted or unsubstituted non-aromatic heterocyclic sulfinyl group, a substituted or unsubstituted aromatic carbocyclic sulfonyl group, a substituted or unsubstituted non-aromatic carbocyclic sulfonyl group, a substituted or unsubstituted aromatic heterocyclic sulfonyl group, or a substituted or unsubstituted non-aromatic heterocyclic sulfonyl group. R 16 Preferred aspects include: substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclic group, substituted or unsubstituted non-aromatic carbocyclic group, substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aromatic carbocyclic carbonyl, substituted or unsubstituted non-aromatic carbocyclic carbonyl, substituted or unsubstituted aromatic heterocyclic carbonyl, or substituted or unsubstituted non-aromatic heterocyclic carbonyl. R 16Preferred aspects of include: substituted or unsubstituted alkyl, aromatic carbocyclic group which may be substituted by substituent group B, non-aromatic carbocyclic group which may be substituted by substituent group B, aromatic heterocyclic group which may be substituted by substituent group B, non-aromatic heterocyclic group which may be substituted by substituent group B, aromatic carbocyclic carbonyl which may be substituted by substituent group B, non-aromatic carbocyclic carbonyl which may be substituted by substituent group B, aromatic heterocyclic carbonyl which may be substituted by substituent group B, or non-aromatic heterocyclic carbonyl which may be substituted by substituent group B. R 16 Particularly preferred aspects include: an aromatic carbocyclic group which may be substituted with the substituent group B. R 16 Examples of the substituent when substituted include halogen, alkyl, haloalkyl, an aromatic carbocyclic group which may be substituted with a substituent group B, a non-aromatic carbocyclic group which may be substituted with a substituent group B, an aromatic heterocyclic group which may be substituted with a substituent group B, and a non-aromatic heterocyclic group which may be substituted with a substituent group B.

[0055] The compound of the present invention is characterized in that it has the characteristic of inhibiting MGAT2 by being a dihydropyrazolopyrazinone derivative represented by formula (I). Furthermore, in terms of other characteristics, the dihydropyrazolopyrazinone derivative represented by formula (I) has a structure in which a pyrazole ring is condensed on a dihydropyrazinone ring, thereby avoiding an enone structure and inhibiting toxicity. As for further characteristics of the dihydropyrazolopyrazinone derivative represented by formula (I), it can be cited that it has high solubility and metabolic stability, and high stability in acidic solutions.

[0056] The compound represented by formula (I) is not limited to specific isomers, and includes all possible isomers (eg, keto-enol isomers, imine-enamine isomers, diastereomers, optical isomers, rotational isomers, etc.), racemates or mixtures thereof.

[0057] One or more hydrogen, carbon and / or other atoms of the compound represented by formula (I) may be replaced by isotopes of hydrogen, carbon and / or other atoms, respectively. Examples of such isotopes are 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F. 123 I and 36Cl, etc., including hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine. The compound represented by formula (I) also includes compounds substituted with such isotopes. The compounds substituted with such isotopes can be used as pharmaceuticals, including all radioactive markers of the compound represented by formula (I). In addition, the "radioactive labeling method" for producing the "radioactive marker" is also included in the present invention, and the "radioactive marker" can be used as a tool for research and / or diagnosis in metabolic drug dynamics research and bonding analysis.

[0058] The radioactive label of the compound represented by formula (I) can be prepared by methods known in the art. For example, the tritium-labeled compound represented by formula (I) can be prepared by introducing tritium into the specific compound represented by formula (I) through a dehalogenation reaction using a tritium catalyst. The method comprises reacting a precursor of the compound represented by formula (I) after appropriate halogen substitution with tritium gas in the presence of a suitable catalyst, such as Pd / C, in the presence or absence of a base. Other suitable methods for preparing tritium-labeled compounds can be found in "Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987)". 14 C-labeled compounds can be obtained by using 14 C carbon raw materials are prepared.

[0059] Pharmaceutically acceptable salts of the compound represented by formula (I) include, for example, salts of the compound represented by formula (I) with alkali metals (e.g., lithium, sodium, potassium, etc.), alkaline earth metals (e.g., calcium, barium, etc.), magnesium, transition metals (e.g., zinc, iron, etc.), ammonia, organic bases (e.g., trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, pyridine, picoline, quinoline, etc.) and amino acids, or salts with inorganic acids (e.g., hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid, etc.), and organic acids (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, etc.). Particularly, salts with hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, methanesulfonic acid, etc. can be mentioned. The above salts can be formed by commonly used methods.

[0060] The compound represented by formula (I) of the present invention or its pharmaceutically acceptable salt may form a solvate (e.g., hydrate, etc.), cocrystal and / or crystalline polymorph, and the present invention also includes various solvates, cocrystals and crystalline polymorphs of this type. "Solvate" means that the compound represented by formula (I) can be coordinated with any number of solvent molecules (e.g., water molecules, etc.). By placing the compound represented by formula (I) or its pharmaceutically acceptable salt in the atmosphere, it absorbs moisture, thereby producing attached adsorbed water, or forming a hydrate. In addition, there is also a situation in which a crystalline polymorph is formed by recrystallizing the compound represented by formula (I) or its pharmaceutically acceptable salt. "Cocrystal" means that the compound or salt represented by formula (I) and the cocrystal coordination molecule (counter molecule) exist in the same crystal lattice, and can also be formed with any number of cocrystal coordination molecules.

[0061] The compound represented by formula (I) of the present invention or its pharmaceutically acceptable salt is a case where a prodrug is formed, and the present invention also includes various prodrugs of this type. A prodrug is a derivative of the compound of the present invention having a chemically or metabolically decomposable group, which is a compound that becomes a pharmaceutically active compound of the present invention in vivo by solvent decomposition or under physiological conditions. A prodrug is a compound that is converted into a compound represented by formula (I) by enzymatic oxidation, reduction, hydrolysis, etc. under physiological conditions in vivo, a compound that is converted into a compound represented by formula (I) by hydrolysis such as gastric acid, etc. The selection method and preparation method of appropriate prodrug derivatives can be referred to, for example, the records of "Design of Prodrugs, Elsevier, Amsterdam, 1985". There are also cases where the prodrug itself is active.

[0062] When the compound represented by formula (I) or a pharmaceutically acceptable salt thereof has a hydroxyl group, for example, by reacting the compound having a hydroxyl group with a suitable acyl halide, a suitable acid anhydride, a suitable sulfonyl chloride, a suitable sulfonyl anhydride and a mixed acid anhydride, or by reacting it with a condensing agent, a prodrug such as an acyloxy derivative or a sulfonyloxy derivative can be prepared. Examples thereof include CH3COO-, C2H5COO-, tert-BuCOO-, C 15 H 31 COO-, PhCOO-, (m-NaOOCPh)COO-, NaOOCCH2CH2COO-, CH3CH(NH2)COO-, CH2N(CH3)2COO-, CH3SO3-, CH3CH2 SO3-, CF3SO3-, CH2FSO3-, CF3CH2SO3-, p-CH3O-PhSO3-, PhSO3-, p-CH3PhSO3-.

[0063] (Method for producing the compound of the present invention) The compound represented by formula (I) of the present invention can be produced, for example, by the following general synthesis method, and can be processed by conventional organic chemical experiments such as extraction and purification. The compounds of the present invention can be synthesized by referring to techniques well known in the art.

[0064] (General synthesis method) The compound represented by formula (I) of the present invention (hereinafter referred to as a17) can be produced, for example, by the following production method. (In the formula, each symbol has the same meaning as above) Step A-1 Compound a2 can be obtained by reacting compound a1 with tert-butylsulfenamide and tetraisopropoxytitanium or tetraethoxyethane. The reaction temperature is 20°C to 120°C, preferably 70°C to 100°C. The reaction time is 1 to 12 hours, preferably 3 to 6 hours. Examples of the reaction solvent include tetrahydrofuran, 2-methyltetrahydrofuran, and toluene. Step A-2 After reacting a3 with a base such as lithium diisopropylamide or lithium bis(trimethylsilyl)amide, triisopropoxytitanium chloride or the like is added as needed, and the reaction is carried out with compound a2 to obtain compound a4. Examples of R in compound a3 include methyl, ethyl, and tert-butyl. The reaction temperature is -78°C to -20°C for the reaction of a base such as lithium diisopropylamide or lithium bis(trimethylsilyl)amide with ester a3 and the subsequent reaction with compound a2. The reaction time of the base and the ester a3 is 30 minutes to 2 hours, and the subsequent reaction with the compound a2 is 1 to 5 hours. Examples of the reaction solvent include tetrahydrofuran and diethyl ether. Step A-3 Compound a4 is reacted with an acid or a Lewis acid, and then reacted with Boc2O in the presence of a base to obtain compound a5. Examples of the acid include hydrochloric acid-ethyl acetate, hydrochloric acid-methanol, hydrochloric acid-dioxane, sulfuric acid, formic acid, trifluoroacetic acid, etc. Examples of the Lewis acid include trimethylsilyl iodide, BBr3, AlCl3, BF3·(Et2O), etc., and can be used in 1 to 10 molar equivalents relative to compound a4. Examples of the base include sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, calcium carbonate, cesium carbonate, pyridine, triethylamine, and the like, and 3 to 15 molar equivalents can be used relative to compound a4. The reaction temperature is 0°C to 60°C, preferably 0°C to 20°C. The reaction time is 0.5 to 24 hours, preferably 6 to 18 hours. Examples of the reaction solvent include methanol, ethanol, water, acetone, acetonitrile, and DMF, which can be used alone or in combination. Step A-4 Compound a6 can be obtained by reacting compound a5 with a reducing agent. Examples of the reducing agent include lithium borohydride and lithium aluminum hydride, and the reducing agent can be used in an amount of 1 to 10 molar equivalents relative to compound a5. The reaction temperature is from 0°C to reflux temperature, preferably from 20°C to reflux temperature. The reaction time is 0.2 to 48 hours, preferably 1 to 24 hours. Examples of the reaction solvent include methanol, ethanol, propanol, isopropanol, butanol, tetrahydrofuran, diethyl ether, dichloromethane, and water, and these solvents may be used alone or in combination. Step A-5 Compound a7 can be obtained by reacting compound a6 with an oxidizing agent such as 2-iodooxybenzoic acid or Dess Martin periodinane. The reaction temperature is -10°C to 50°C, preferably 0°C to 30°C. The reaction time is 1 to 24 hours, preferably 5 to 20 hours. As the reaction solvent, dimethyl sulfoxide or the like can be used. Step A-6 Compound a8 can be obtained by reacting compound a7 with osmium tetroxide, 4-methylmorpholine, 4-methylmorpholine N-oxide, sodium periodate or the like. The reaction temperature is -10°C to 50°C, preferably 0°C to 30°C. The reaction time is 1 to 24 hours, preferably 5 to 20 hours. As the reaction solvent, a mixed solvent of acetone and water or the like can be used. Step A-7 Compound a10 can be obtained by reacting compound a8 with a nucleophile a9. Nucleophilic reagent a9 includes lithium reagents such as methyllithium and ethyllithium, or Grignard reagents such as methylmagnesium bromide, methylmagnesium chloride, methylmagnesium iodide, ethylmagnesium bromide, ethylmagnesium chloride, ethylmagnesium iodide, and mixed reagents thereof with metal salts, and can be used in an amount of 1 to 5 molar equivalents relative to compound a8. The reaction temperature is from -78°C to the reflux temperature of the solvent, preferably from -45°C to 0°C. The reaction time is 0.5 to 24 hours, preferably 1 to 6 hours. Examples of the reaction solvent include tetrahydrofuran, hexane, diethyl ether, methyl tert-butyl ether, toluene, dichloromethane, and methanol, which can be used alone or in combination. The nucleophilic reagent a9 can be adjusted by lithiating a halogenide using an alkyl lithium such as n-butyl lithium. The reaction solvent is not particularly limited as long as it is a solvent that does not react with alkyl lithium, such as tetrahydrofuran and dioxane. The temperature of the lithiation reaction is preferably about -78°C to 0°C. Alternatively, by substituting the nucleophilic reagent a9 and reacting it with a reducing agent such as sodium borohydride, lithium borohydride, or lithium aluminum hydride, R 3b A compound of hydrogen. Step A-8 Compound a11 can be obtained by reacting compound a10 with thionyl chloride and a base. Examples of the base include pyridine and triethylamine, and the base can be used in an amount of 1 to 5 molar equivalents relative to compound a10. The reaction temperature is -10°C to 50°C, preferably 0°C to 30°C. The reaction time is 1 to 24 hours, preferably 5 to 10 hours. The reaction solvent that can be used is acetonitrile, dioxane, tetrahydrofuran, DMF, etc. Step A-9 Compound a12 can be obtained by reacting compound a11 with ruthenium chloride hydrate, sodium periodate, or the like. The reaction temperature is -10°C to 50°C, preferably 0°C to 30°C. The reaction time is 1 to 24 hours, preferably 5 to 20 hours. As the reaction solvent, a mixed solvent of ethyl acetate and water or the like can be used. Step A-10 Compound a14 can be obtained by reacting Compound a12 with Compound a13 and a base. Examples of the base include sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, calcium carbonate, cesium carbonate, pyridine, triethylamine, and the like, and 1 to 5 molar equivalents can be used relative to compound a13. The reaction temperature is 0°C to 150°C, preferably 50°C to 100°C. The reaction time is 0.5 to 24 hours, preferably 1 to 5 hours. Examples of the reaction solvent include methanol, ethanol, acetonitrile, and DMF, which can be used alone or in combination. Step A-11 Compound a15 can be obtained by reacting compound a14 with a base. Examples of the base include sodium hydroxide, potassium hydroxide, sodium hydride, and the like, and 1 to 5 molar equivalents can be used relative to compound a14. The reaction temperature is 0°C to 100°C, preferably 0°C to 30°C. The reaction time is 0.5 to 24 hours, preferably 1 to 5 hours. Examples of the reaction solvent include methanol, ethanol, acetonitrile, water, and DMF, which can be used alone or in combination. Step A-12 Compound a16 can be obtained by reacting compound a15 with an acid or a Lewis acid. Examples of the acid include hydrochloric acid-ethyl acetate, hydrochloric acid-methanol, hydrochloric acid-dioxane, sulfuric acid, formic acid, trifluoroacetic acid, etc. Examples of the Lewis acid include trimethylsilyl iodide, BBr3, AlCl3, BF3·(Et2O), etc., and can be used in an amount of 1 to 50 molar equivalents relative to compound a15. The reaction temperature is 0°C to 60°C, preferably 0°C to 20°C. The reaction time is 0.5 to 24 hours, preferably 6 to 18 hours. Examples of the reaction solvent include ethyl acetate, methanol, ethanol, water, acetone, acetonitrile, and DMF, which can be used alone or in combination. Step A-13 Compound a17 can be obtained by reacting compound a16 with a condensing agent and a base. Examples of the condensing agent include dicyclohexylcarbodiimide, carbonyldiimidazole, dicyclohexylcarbodiimide-N-hydroxybenzotriazole, EDC, 4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methylmorpholinium chloride, and HATU, and 1 to 5 molar equivalents can be used relative to compound a16. Examples of the base include triethylamine and diisopropylethylamine, and 1 to 5 molar equivalents can be used based on compound a16. The reaction temperature is -20°C to 60°C, preferably 0°C to 30°C. The reaction time is 0.1 to 24 hours, preferably 1 to 5 hours. The reaction solvents include DMF, DMA, NMP, tetrahydrofuran, dioxane, dichloromethane, acetonitrile, etc., which can be used alone or in combination.

[0065] The compound of the present invention has MGAT2 inhibitory effect and can be used as a preventive or therapeutic agent for obesity, metabolic syndrome, hyperlipidemia, high-grade lipidemia, high VLDLemia, hyperfatty acidemia, diabetes, arteriosclerosis and the like. The compounds of the present invention not only have MGAT2 inhibitory effects, but also have practicality as drugs and have any or all of the following excellent characteristics. a) High metabolic stability. b) Shows high solubility. c) Little concern about phototoxicity. d) Little concern about hepatotoxicity. e) There is little concern about nephrotoxicity. f) There is little concern about cardiovascular toxicity. g) There is little concern about gastrointestinal obstruction. h) There is little concern about drug interactions. i) High oral absorbability. j) The clearance rate is low. k) High migration ability to target tissues. l) Strong enzyme activity. m) Less induction of drug metabolizing enzymes. n) Strong efficacy. o) MGAT2 inhibition is highly selective. p) High chemical stability.

[0066] The pharmaceutical composition of the present invention can be delivered by any method, either orally or parenterally. Examples of parenterally delivered methods include transdermal, subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, transmucosal, inhalation, nasal, eye drop, ear drop, vaginal delivery, etc.

[0067] In the case of oral delivery, the drug can be prepared into any of the following commonly used dosage forms according to common methods: solid preparations for internal use (e.g., tablets, powders, granules, capsules, pills, films, etc.), liquid preparations for internal use (e.g., suspensions, emulsions, elixirs, syrups, lemon preparations, alcohol preparations, aromatic water preparations, extracts, decoctions, tinctures, etc.), etc. Tablets can be sugar-coated tablets, film-coated tablets, enteric-coated tablets, sustained-release tablets, buccal tablets, sublingual tablets, buccal tablets, chewable tablets, or orally disintegrating tablets; powders and granules can be dry syrups; capsules can be soft capsules, microcapsules, or sustained-release capsules.

[0068] In the case of parenteral delivery, any of the following commonly used dosage forms can be appropriately delivered: injections, drops, external preparations (e.g., eye drops, nose drops, ear drops, sprays, inhalants, detergents, infusions, coatings, mouthwashes, enema, ointments, plasters, gels, emulsions, patches, poultices, external powders, suppositories, etc.), etc. Injections can be emulsions of O / W, W / O, O / W / O, W / O / W type, etc.

[0069] The effective amount of the compound of the present invention can be mixed with various pharmaceutical additives such as excipients, binders, disintegrants, lubricants suitable for its dosage form as required to prepare a pharmaceutical composition. Further, the pharmaceutical composition can also be made into a pharmaceutical composition for children, the elderly, critically ill patients or surgery by appropriately changing the effective amount, dosage form and / or various pharmaceutical additives of the compound of the present invention. The pharmaceutical composition for children is preferably delivered to patients under 12 or 15 years old. Furthermore, the pharmaceutical composition for children can be delivered to patients under 27 days after birth, 28 days to 23 months after birth, 2 to 11 years old, 12 to 16 years old or 18 years old. The pharmaceutical composition for the elderly is preferably delivered to patients over 65 years old.

[0070] The delivery amount of the pharmaceutical composition of the present invention is preferably set in consideration of the patient's age, weight, type or degree of disease, delivery route, etc., but when delivered orally, it is usually in the range of 0.05 to 100 mg / kg / day, preferably 0.1 to 10 mg / kg / day. When delivered parenterally, there is a large difference depending on the delivery route, but it is usually in the range of 0.005 to 10 mg / kg / day, preferably 0.01 to 1 mg / kg / day. It is preferably delivered once or more per day.

[0071] The delivery amount of the combined drug can be appropriately selected based on the clinically used amount. Furthermore, the blending ratio of the compound of the present invention and the combined drug can be appropriately selected according to the delivery target, delivery route, target disease, symptoms, combination, etc. For example, when the delivery target is a human, 0.01 to 100 parts by weight of the combined drug can be used relative to 1 part by weight of the compound of the present invention.

[0072] The pharmaceutical composition of the present invention is for treating obesity (however, it is limited to patients with both type 2 diabetes and dyslipidemia, and BMI is still 25 kg / m even after diet therapy / exercise therapy). 2 The above situations) are also valid.

[0073] The pharmaceutical composition of the present invention is effective also for severe obesity for which diet therapy and exercise therapy are insufficiently effective.

[0074] The pharmaceutical composition of the present invention can also be used in combination with other anti-obesity drugs (a pharmaceutical composition containing a compound with an anti-obesity effect, which can be used for obesity, weight management in obesity, etc.). For example, a pharmaceutical composition containing a compound with an anti-obesity effect is used in combination with the compound of the present invention, thereby, it can be used for the prevention and / or treatment of obesity, weight management in obesity, etc. Furthermore, a pharmaceutical composition containing the compound of the present invention is used in combination with a pharmaceutical composition containing a compound with an anti-obesity effect, thereby, it can be used for the prevention and / or treatment of obesity, weight management in obesity, etc. Furthermore, the delivery therapy of the pharmaceutical composition of the present invention can also be used in combination with diet therapy, drug therapy, exercise, etc.

[0075] The abbreviations used in this specification have the following meanings. Boc: tert-Butyloxycarbonyl DMA: dimethylacetamide DMF: N,N-dimethylformamide DMSO: dimethyl sulfoxide EDC: 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide Et: Ethyl HATU: O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate NMP: N-methyltetrahydropyrrolidone

[0076] The present invention will be described in more detail below with reference to Examples and Test Examples, but the present invention is not limited thereto. The NMR spectra of the compounds of the present invention and their intermediates are shown in Table 1. The NMR analysis obtained in each example was performed at 400 MHz using deuterated chloroform (CDCl3) or dimethyl sulfoxide (d6-DMSO). [Example 1]

[0077] Step 1 Synthesis of Compound 2 (R)-2-methylpropane-2-sulfenamide (631 mg, 5.21 mmol) was dissolved in toluene (2.5 mL), and tetraethoxytitanium (0.654 mL, 3.12 mmol) was added. Then, the known compound 1 (384 mg, 2.08 mmol) was dissolved and added to toluene (2.5 mL), and stirred at 100 ° C for 3 hours. Then, at room temperature, citric acid aqueous solution and ethyl acetate were added, the insoluble matter was filtered, and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain compound 2 (428 mg, yield 72%). 1 H-NMR(CDCl3)δ:1.32(s,9H),3.31-3.38(m,1H),3.45-3.52(m,1H),4.27-4.33(m,1H),4.36-4.41(m,1H),6.43-6.49(m,2H). Step 2 Synthesis of compound 3 Tetrahydrofuran (1 mL) and methyl acetate (0.178 mL, 2.23 mmol) were added to a 1M tetrahydrofuran solution of lithium bis(trimethylsilyl)amide (2.23 mL, 2.23 mmol) at -78°C and stirred for 1 hour. Then, a 1M hexane solution of triisopropoxytitanium chloride (2.98 mL, 2.98 mmol) was added dropwise at -78°C and stirred for 30 minutes. Then, compound 2 (428 mg, 1.49 mmol) was dissolved in tetrahydrofuran (1 mL) and added dropwise at -78°C and stirred for 4 hours. Then, a 10% aqueous solution of citric acid and potassium sodium tartrate were added, the mixture was heated to room temperature and stirred for 12 hours. Then, extraction was performed using ethyl acetate, and the organic layer was washed with a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution, and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography to obtain Compound 3 (305 mg, yield 57%). 1 H-NMR(CDCl3)δ:1.22(s,9H),2.19-2.27(m,1H),2.45-2.49(m,1H),2.74(d,J=15.9Hz,1H),3.40(d ,J=15.9Hz,1H),3.70(s,3H),4.19-4.24(m,1H),4.51-4.57(m,1H),5.02(s,1H),6.36-6.47(m,2H). Step 3 Synthesis of compound 4 Compound 3 (2.31 g, 6.40 mmol) was dissolved in methanol (18.5 mL), 4 mol / L hydrochloric acid dioxane solution (3.20 mL, 12.8 mmol) was added, and the mixture was stirred at room temperature for 1 hour and 15 minutes. It was diluted with water (9.3 mL), sodium bicarbonate (1.61 g, 19.2 mmol) and di-tert-butyl dicarbonate (2.79 g, 12.8 mmol) were added, and the mixture was further stirred at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure, and after further azeotropic dehydration with ethyl acetate, it was diluted with ethyl acetate and the insoluble matter was filtered. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain compound 4 (1.85 g, purity 96.1%, yield 78%). 1 H-NMR(CDCl3)δ:6.42-6.33(2H,m),5.50(1H,s),4.27-4.13(2H,m),3.64(3H,s),3.37- 3.30(1H,m),3.04(1H,d,J=14.6Hz),2.91-2.82(1H,m),2.27-2.18(1H,m),1.38(9H,br s). Step 4 Synthesis of Compound 5 Compound 4 (1.85 g, 4.97 mmol) was dissolved in tetrahydrofuran (9.3 mL), and a 1 mol / L tetrahydrofuran solution of lithium borohydride (2.50 ml, 2.50 mmol) was added at -78 °C, and stirred at room temperature for 18.5 hours. Ice was added to the reaction solution, and then a 2 mol / L aqueous hydrochloric acid solution was added and set to pH 4, and then extracted with ethyl acetate. The solvent was distilled off under reduced pressure, and the obtained residue was dissolved in dimethyl sulfoxide (9.1 mL), 2-iodineoxybenzoic acid (2.09 g, 7.46 mmol) was added, and stirred at room temperature for 19.5 hours, and then 2-iodineoxybenzoic acid (0.418 g, 1.41 mmol) was further added and stirred for 4 hours. Ethyl acetate and water were added to the reaction solution, the precipitated solid was filtered out, the organic layer was washed with water, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain Compound 5 (1.70 g, purity 94.4%, yield 99%). 1H-NMR(CDCl3)δ:9.65(1H,q,J=1.7Hz),6.45-6.36(2H,m),5.03(1H,s),4.23(1H,tt,J=11.3,4.0Hz),4.18(1H,td,J=11.3,2 .3Hz), 3.59-3.51(1H,m), 3.34(1H,dt,J=17.1,1.7Hz), 2.96-2.88(1H,m), 2.19(1H,ddd,J=14.2,10.9,4.1Hz), 1.42(9H,s). Step 5 Synthesis of Compound 6 Compound 5 (1.70 g, 4.89 mmol) was dissolved in acetone (30 mL) and water (3 mL), and 5% microencapsulated osmium tetroxide (0.889 g, 0.245 mmol), 4-methylmorpholine (1.24 g, 12.2 mmol), 4-methylmorpholine N-oxide (1.15 g, 9.79 mmol), and sodium periodate (6.07 g, 24.5 mmol) were added, and stirred at room temperature for 15 hours. The reaction solution was concentrated under reduced pressure, diluted with ethyl acetate and water, and sodium thiosulfate pentahydrate (6.07 g, 24.5 mmol) was added. After filtering to remove insoluble matter, the organic layer was washed with water, and the solvent was distilled off under reduced pressure. The obtained residue was dissolved in methanol (12 mL), sodium borohydride (93.0 mg, 2.45 mmol) was added, and stirred at room temperature for 20 minutes. The reaction solution was concentrated under reduced pressure and diluted with water, and then 2 mol / L hydrochloric acid aqueous solution was added and set to pH 4, and then extracted with ethyl acetate, and the organic layer was washed with water and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain compound 6 (1.06 g, yield 68%). 1 H-NMR(CDCl3)δ:6.43-6.37(2H,m),5.17(1H,s),4.49-4.44(1H,m),4.28-4 .14(3H,m),3.70(1H,dd,J=11.4,10.1Hz),2.51-2.36(2H,m),1.42(9H,s). Step 6 Synthesis of Compound 7 A solution of compound 6 (1.05 g, 3.32 mmol) in acetonitrile (12 mL) was added dropwise at -50°C to a solution of thionyl chloride (1.22 g, 10.3 mmol) in acetonitrile (10 mL). After stirring at the same temperature for 1 hour, pyridine (1.05 g, 23.3 mmol) was added and stirred at room temperature for 3 hours. After dilution with water, extraction was performed with ethyl acetate. After washing with water, the solvent was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain compound 7 (1.09 g, purity 91.2%, yield 83%) as a mixture of diastereoisomers with a ratio of 92.6:7.4. The two diastereoisomers were not separated and used directly in the subsequent step. Step 7 Synthesis of Compound 8 Compound 7 (1.08 g, 2.73 mmol) was dissolved in ethyl acetate (10 mL) and water (10 mL), and ruthenium chloride hydrate (3.0 mg, 0.01 mmol) and sodium periodate (642 mg, 3.00 mmol) were added at 0 ° C and stirred at room temperature for 2 hours. At room temperature, water (10 mL) was added, and then ruthenium chloride hydrate (2.1 mg, 0.01 mmol) and sodium periodate (117 mg, 0.546 mmol) were added, and further stirred at room temperature for 3 hours. Ethyl acetate was used for extraction, and after washing, it was filtered through a column filled with dry silica gel. After the filtrate was concentrated under reduced pressure, it was powdered using hexane-ethyl acetate, thereby obtaining compound 8 (873 mg, yield 85%). 1 H-NMR (DMSO-D6) δ: 6.93 (1H, ddd, J = 11.4, 9.2, 2.7Hz), 6.72 (1H, dt, J = 10.1, 2.0Hz), 5.09 (1H, d, J = 10.2Hz), 4.63 (1H, dd,J=10.2,1.0Hz),4.42(1H,ddd,J=12.2,4.0,2.6Hz),4.22(1H,td,J=12.4,2.0Hz),2.47-2.32(2H,m),1.22(9H,s). Step 8 Synthesis of compound 10 Compound 9 (110 mg, 0.439 mmol) was dissolved in DMF (4 mL), potassium carbonate (60.6 mg, 0.439 mmol) was added and heated to 100° C., compound 8 (151 mg, 0.399 mmol) was added and stirred at 100° C. for 40 minutes. After dilution with water, extraction was performed using ethyl acetate, and after washing with water, the solvent was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain compound 10 (151 mg, purity 96.3%, yield 67%). 1 H-NMR(CDCl3)δ:8.42(1H,d,J=2.8Hz),8.01-7.95(1H,m),7.46(1H,td,J=8.5,2.8Hz),6.84(1H,s),6.44-6.32(2H,m),5. 87(2H,s),5.15-4.86(2H,m),4.44-4.19(4H,m),2.68-2.91(1H,m),1.90-1.81(1H,m),1.42(3H,t,J=7.2Hz),1.32(9H,br s). Step 9 Synthesis of compound 11 Compound 10 (150 mg, 0.439 mmol) was dissolved in DMF (4 mL), 60% sodium hydride (42.3 mg, 1.06 mmol) was added, and the mixture was stirred at room temperature for 1 hour. After dilution with ice, 1 mol / L aqueous hydrochloric acid solution was added and the pH was adjusted to 4, and extraction was performed with ethyl acetate. After washing with water, the solvent was concentrated under reduced pressure, and 4 mol / L dioxane hydrochloride (4 mL, 16.0 mmol) was added to the obtained residue, and the mixture was stirred at room temperature for 1 hour. The solvent was concentrated under reduced pressure, diluted with DMF (6 mL), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (151 mg, 0.398 mmol) and triethylamine (0.257 mL, 1.86 mmol) were added, and the mixture was stirred at room temperature for 30 minutes. Water was added and extraction was carried out with ethyl acetate. After washing with water, the solvent was concentrated under reduced pressure and the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate, silica gel) to obtain compound 11 (59.5 mg, purity 97.4%, yield 55%). 1 H-NMR(CDCl3)δ:8.43(1H,d,J=2.9Hz), 7.96(1H,dd,J=8.9,4.5Hz), 7.45(1H,td,J=8.6,2.9Hz), 6.54 -6.49(2H,m),5.75(1H,s),5.68(2H,s),4.77(1H,d,J=13.1Hz),4.29-4.19(3H,m),2.37-2.21(2H,m). Step 10 Synthesis of Compound I-119 Compound 11 (30.8 mg, 0.075 mmol) and 2-(methylsulfonyl)acetic acid (20.6 mg, 0.149 mmol) were dissolved in tetrahydrofuran (4 mL), O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (56.8 mg, 0.149 mmol) and triethylamine (0.041 mL, 0.299 mmol) were added and stirred at room temperature for 2 hours. Water was added and extracted with ethyl acetate, washed with water, and the solvent was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform-methanol, amino silica gel) to obtain compound I-119 (35.4 mg, purity 97.0%, yield 88%). 1 H-NMR(DMSO-D6)δ:10.07(1H,s),8.97(1H,s),8.56(1H,d,J=2.8Hz),7.89 (1H,dd,J=8.8,4.6Hz),7.77(1H,td,J=8.8,2.8Hz),6.91(1H,ddd,J=11.0, 9.2,2.2Hz),6.74-6.70(1H,m),4.76(1H,d,J=13.6Hz),4.71(1H,d,J=13.6 Hz),4.39-4.19(3H,m),3.17(3H,s),2.25-2.19(1H,m),2.10-2.02(1H,m). [Example 2]

[0078] Step 1 Synthesis of compound 9 60% sodium hydride (314 mg, 7.86 mmol) was added to ethanol (20 mL) at 0°C. After stirring for 10 minutes, the known compound 12 (1.00 g, 7.15 mmol) and 88.3% ethyl diazoacetate (1.02 g, 7.86 mmol) were added dropwise and stirred at room temperature for 5 hours. A 2 mol / L aqueous hydrochloric acid solution was added to the reaction solution at 0°C and the pH was adjusted to 8.6, and then extracted with ethyl acetate. After washing with water, most of the solvent was distilled off under reduced pressure, and the mixture was powdered using hexane-ethyl acetate, thereby obtaining compound 9 (1.49 g, yield 84%). 1 H-NMR(CDCl3)δ:8.42(1H,d,J=3.0Hz), 8.02(1H,dd,J=8.8,4.5Hz), 7.46(1H,td,J=8.5,3.0Hz), 5.66(2H,br s), 4.42 (2H, q, J = 7.2Hz), 1.43 (3H, t, J = 7.2Hz).

[0079] The following compounds were synthesized in the same manner. The following are the physical data of each compound. In the table, "RT" represents the retention time (minutes) in LC / MS (liquid chromatography / mass spectrometry), "MS" represents the mass (M+H) in LC / MS, and "LCMS method" represents any one of the following measurement conditions of LC / MS. [Measurement Condition A] Column: ACQUITY UPLC (registered trademark) BEH C18 (1.7 μm i.d. 2.1 x 50 mm) (Waters) Flow rate: 0.55mL / min UV detection wavelength: 254nm Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile solution containing 0.1% formic acid Gradient: A linear gradient from 5% to 100% solvent [B] was performed in 3 minutes, followed by a 0.5 minute maintenance at 100% solvent [B]. [Measurement Condition B] Column: ACQUITY UPLC (registered trademark) BEH C18 (1.7 μm i.d. 2.1 x 50 mm) (Waters) Flow rate: 0.8 mL / min UV detection wavelength: 254nm Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile solution containing 0.1% formic acid After a linear gradient from 5% to 100% solvent [B] was performed in 3.5 minutes, 100% solvent [B] was maintained for 0.5 minutes. [Measurement Condition C] Column: ACQUITY UPLC (registered trademark) BEH C18 (1.7 μm i.d. 2.1 x 50 mm) (Waters) Flow rate: 0.8 mL / min UV detection wavelength: 254nm Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile solution containing 0.1% formic acid After a linear gradient from 5% to 100% solvent [B] was performed in 3.5 minutes, 100% solvent [B] was maintained for 0.5 minutes. [Measurement Condition D] Column: Shim-pack XR-ODS (2.2μm id50x3.0mm) (Shimadzu) Flow rate: 1.6mL / min UV detection wavelength: 254nm; Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile solution containing 0.1% formic acid Gradient: A linear gradient from 10% to 100% solvent [B] was performed in 3 minutes, followed by a 0.5 minute maintenance at 100% solvent [B].

[0080] [Table 1]

[0081] [Table 2]

[0082] [Table 3]

[0083] [Table 4]

[0084] [Table 5]

[0085] [Table 6]

[0086] [Table 7]

[0087] [Table 8]

[0088] [Table 9]

[0089] [Table 10]

[0090] [Table 11]

[0091] [Table 12]

[0092] [Table 13]

[0093] [Table 14]

[0094] [Table 15]

[0095] [Table 16]

[0096] [Table 17]

[0097] [Table 18]

[0098] [Table 19]

[0099] [Table 20]

[0100] [Table 21]

[0101] [Table 22]

[0102] In addition, I-54 and I-55 are mixtures in which the asymmetric carbon atoms of the parent nucleus are R / S=1 / 1. I-62 and I-63 have a single stereo configuration of the parent core, but the absolute configuration has not been determined. I-72, I-105, I-106 and I-107 are single stereo configurations of sulfonimide, but the absolute configurations are not determined. I-73, I-108 and I-112 are mixtures of sulfonyl imide with a stereo configuration of R / S=1 / 1.

[0103] [Table 23]

[0104] The following are biological test examples of the compounds of the present invention. The compound represented by formula (I) of the present invention has an MGAT2 inhibitory effect. In the evaluation method specifically described below, IC50 is preferably 100 nM or less, more preferably 50 nM or less, and even more preferably 10 nM or less.

[0105] Preparation Example 1: Preparation of recombinant human MGAT2 The full-length human MGAT2 gene with a Flag-tag attached to the N-terminus was inserted into pFastBac (Invitrogen). According to the protocol of the Bac-to-Bac baculovirus expression system (Invitrogen), a recombinant baculovirus was prepared and Sf-9 cells were infected. After the recovered cells were ultrasonically broken, they were separated by centrifugal recovery membrane. Expression was confirmed by Western blot analysis using anti-Flag antibodies to prepare a recombinant human MGAT2 enzyme solution.

[0106] Test Example 1: Determination of human MGAT2 inhibitory activity To a 384-well polystyrene microplate manufactured by Corning to which 0.2 μL of a DMSO solution of each compound of the present invention was dispensed, 5 μL of an enzyme solution prepared with an assay buffer (100 mmol / L phosphate buffer (pH 7.4) containing 2 mmol / l DTT) and 5 μL of a substrate solution (100 mmol / L phosphate buffer (pH 7.4), 30 μmol / L 2-oleoylglycerol, 10 μmol / L oleoyl-CoA) were added, stirred and centrifuged, and then incubated in a humidified chamber at room temperature for 1 hour. After the enzyme reaction, the reaction was stopped by adding 50 μL of a stop solution containing an internal standard (IS) (containing 0.2 μmol / L diolein-d5, 0.4% formic acid and 50% isopropanol), and the reaction was sealed in a Shimadzu GLC plate, stirred and centrifuged, and measured using RapidFire360 and Agilent 6550Q-TOF mass spectrometers and electrospray ionization. The reaction product (P) of 2-oleoylglycerol, which is a substrate, diolein and ammonium-added ions of IS were detected, and the peak intensity ratio P / IS was calculated using the peak height to evaluate the inhibitory activity. The inhibitory activity was calculated by defining the presence / absence of added enzyme as control (+) / control (-), the inhibition rate as 0% and 100% inhibition, and the peak intensity ratio P / IS when the invention compound was added as the sample, and then calculated using the following formula using TIBCO Spotfire (manufactured by TIBCO Software). Inhibitory activity (%) = [1-{sample-control (-)} / {control (+) control (-)}]*100 The inhibitory activity results of each compound of the present invention are shown in the following table. IC50 (nM) in the table means the concentration showing 50% enzyme inhibition.

[0107] [Table 24]

[0108] Test Example 2: Metabolic stability test Commercially available pooled human liver microsomes were reacted with the compounds of the present invention for a certain period of time, and the residual rate was calculated by comparing the reacted sample with the unreacted sample to evaluate the degree of metabolism of the compounds of the present invention by the liver.

[0109] In 0.2 mL of buffer (50 mmol / L Tris-HCl pH 7.4, 150 mmol / L potassium chloride, 10 mmol / L magnesium chloride) containing 0.5 mg protein / mL of human liver microsomes, the reaction (oxidation reaction) was carried out at 37°C for 0 minutes or 30 minutes in the presence of 1 mmol / L NADPH. After the reaction, 50 μL of the reaction solution was added to 100 μL of a methanol / acetonitrile = 1 / 1 (v / v) solution and mixed, and centrifuged at 3000 rpm for 15 minutes. The compound of the present invention in the centrifugal supernatant was quantified by LC / MS / MS, and the amount of the compound at 0 minutes of reaction was set as 100%, and the residual amount of the compound of the present invention after the reaction was calculated. (Results) The residual ratio at a compound concentration of 0.5 μmol / L is shown below. Compound I-6: 92.4% Compound I-13: 76% Compound I-14: 103% Compound I-20: 74.5% Compound I-33: 98.5% Compound I-46: 78.1% Compound I-58: 88.4% Compound I-61: 95.6% Compound I-66: 105% Compound I-79: 77.2% Compound I-126: 100% Compound I-130: 94.8% Compound I-137: 101% Compound I-141: 99.4% Compound I-142: 106% Compound I-147: 89.8% Compound I-151: 104%

[0110] Test Example 3: Solubility Test: The solubility of the compound of the present invention is determined under the condition of 1% DMSO addition. A 10 mmol / L compound solution is prepared using DMSO, and 6 μL of the compound of the present invention solution is added to 594 μL of pH 6.8 artificial intestinal fluid (1000 mL is prepared by adding 118 mL of 0.2 mol / L NaOH test solution and water to 250 mL of 0.2 mol / L potassium dihydrogen phosphate test solution). After standing at 25°C for 16 hours, the mixed solution is filtered by suction. The filtrate is diluted twice with methanol / water = 1 / 1 (V / V), and the concentration in the filtrate is determined by the absolute calibration curve method using HPLC or LC / MS / MS. In addition, the dilution concentration and the dilution solvent are changed as needed. (result) Compound I-6: >50 μmol / L Compound I-14: 41.8 μmol / L Compound I-46: >50 μmol / L Compound I-58: >50 μmol / L Compound I-66: >50 μmol / L Compound I-79: >50 μmol / L Compound I-126: >50 μmol / L Compound I-130: >50 μmol / L Compound I-137: >50 μmol / L Compound I-141: 48.9 μmol / L Compound I-142: >50 μmol / L Compound I-147: >50 μmol / L Compound I-151: >50 μmol / L

[0111] Test Example 4: Phototoxicity Test In vitro phototoxicity test was conducted by erythrocyte photohemolysis test (Wolfgang JW Pepe et al., ATLA 29, 145-162, 2001), which is an evaluation method using the effect on biological membrane and photoperoxidation as indicators. In this method, a mixed solution (concentration: 0.1 to 0.0008%) of 2.5% (v / v) sheep erythrocyte solution was added to the preparation solution of the compound of the present invention using dimethyl sulfoxide as a medium. Two microplates to which the mixed solution was added were prepared, and one microplate was irradiated with light in the UVA and UVB regions (10 J / cm 2, 290 to 400nm), and then centrifuged together with a microplate that was not irradiated with light, and the absorbance of the supernatant was measured (540nm or 630nm). In order to obtain two indicators used in the determination of phototoxicity (effect on biological membranes and photoperoxidation), the difference in absorbance in the medium after light irradiation and without irradiation was calculated for the absorbance obtained from the compound of the present invention, and provided in the subsequent calculation. Regarding the effect on biological membranes, the photohemolysis rate was calculated from the difference in absorbance (540nm) between light irradiation and non-irradiation, and for photoperoxidation, the change in absorbance (630nm) between light irradiation and non-irradiation was calculated. In addition, in the calculation of the photohemolysis rate, the absorbance (540nm) obtained from 2.5% (v / v) sheep erythrocyte fluid after forced hemolysis using distilled water was used as the basis for the photohemolysis rate of 100%. When the photohemolysis rate was less than 10% and the change in absorbance at 630 nm was less than 0.05, it was regarded as (-), and when the photohemolysis rate was 10% or more and the change in absorbance at 630 nm was 0.05 or more, it was regarded as (+).

[0112] Test Example 5: Cell barrier test The cell-inhibiting activity of the compounds of the present invention was evaluated by automatically measuring the number of cells after compound exposure using Toxinsight (Thermofisher Scientific). HepG2 cells (derived from human liver cancer cells) were seeded in a 384-well plate at 60,000 cells / mL, and compound solutions were added to each well after 24 hours. The compound solution was a DMSO solution containing the compound of the present invention (the highest concentration was set to 50 μmol / L and diluted in 5 stages at a 2-fold ratio, with a lowest concentration of about 3.1 μmol / L), a DMSO-only solution as a negative control, and a camptothecin solution as a positive control. The DMSO solution of the compound of the present invention, the negative control solution, or the positive control solution was added to each well. After 71 hours, a Hoechst 33342 solution diluted with Dulbecco's phosphate buffer (D-PBS) was added to each well to a final concentration of 1 μg / mL, and nuclear staining was performed for 1 hour in a 37°C, 5% CO2 incubator. After staining, fix with 4% triformaldehyde in a 37°C CO2 incubator for 20 minutes. Finally, after washing three times with D-PBS, the number of fluorescent nuclei in each well was measured using Toxinsight (Thermofisher Scientific). Four wells were set for each concentration, and the mean and deviation (SD) of the number of nuclei (the number of cells without obstruction) in the four wells were calculated. Compared with the negative control group, the compound exposure concentration (IC50) at which the mean value was reduced by more than 50% compared with the mean value of the negative control was calculated. The smaller the IC50 value, the higher the risk of cell obstruction.

[0113] Test Example 6: Anti-obesity effect test The anti-obesity effects of the compounds of the examples were examined in C57BL / 6j mice (DIO mice) fed with a high-fat diet (TestDiet; 58Y1). 5-week-old male C57BL / 6j (Clea Japan) were purchased, and a high-fat diet was given under a 12-hour light-dark cycle, and DIO mice were raised for 4 weeks. The medium (0.5% HPMC) was delivered twice a day 3 weeks before the compound was delivered. Randomization was performed according to the changes in body weight and feed intake during the acclimation delivery period, and groups (n=7) were implemented. From the 1st day to the 28th day, forced oral delivery of the example compound or medium (0.5% HPMC) was performed twice a day. Body weight and feed intake were measured every day. Dissection was performed on the 28th day, and the testicular upper body fat weight was measured, and the biochemical examination of the blood collected was performed.

[0114] Test Example 7: CYP inhibition test Commercially available pooled human liver microsomes were used to evaluate the extent to which the production of each metabolite was inhibited by the compounds of the present invention, using O-deethylation of 7-ethoxyresorcinol (CYP1A2), methyl-hydroxylation of tolbutamide (CYP2C9), 4'-hydroxylation of mephenytoin (CYP2C19), O-demethylation of dextromethorphan (CYP2D6), and terfenadine hydroxylation (CYP3A4) as indicators for typical substrate metabolic reactions of major human CYP5 molecular species (CYP1A2, 2C9, 2C19, 2D6, and 3A4). The reaction conditions are as follows: substrate: 0.5 μmol / L ethoxyresorcinol (CYP1A2), 100 μmol / L tolbutamide (CYP2C9), 50 μmol / L S-mephenytoin (CYP2C19), 5 μmol / L dextromethorphan (CYP2D6), 1 μmol / L terfenadine (CYP3A4); reaction time: 15 minutes; reaction temperature: 37°C; enzyme: combined human liver microsomes 0.2 mg protein / mL; concentration of the compound of the present invention: 1, 5, 10, 20 μmol / L (4 points). In a 50 mmol / L Hepes buffer as a reaction solution in a 96-well plate, five substrates, human liver microsomes, and the compound of the present invention were added in the above composition, and NADPH, which is a coenzyme, was added to start the metabolic reaction as an index. After reacting at 37°C for 15 minutes, the reaction was stopped by adding a methanol / acetonitrile = 1 / 1 (V / V) solution. After centrifugation at 3000 rpm for 15 minutes, resorufin (CYP1A2 metabolite) in the centrifugal supernatant was quantified using a fluorescent multi-label counter or LC / MS / MS, and tolbutamide hydroxide (CYP2C9 metabolite), mephenytoin 4' hydroxide (CYP2C19 metabolite), dextrorphan (CYP2D6 metabolite), and terfenadine ethanolate (CYP3A4 metabolite) were quantified using LC / MS / MS. The reaction system in which only DMSO, a solvent for dissolving the drug, was added was used as a control group (100%), and the residual activity (%) was calculated. IC50 was calculated by reverse estimation using the concentration and inhibition rate using a logistic model. (result) Compound I-6: 5 types > 20 μmol / L Compound I-14: 5 types > 20 μmol / L Compound I-20: 5 types > 20 μmol / L Compound I-33: 5 types > 20 μmol / L Compound I-46: 5 types > 20 μmol / L Compound I-58: 5 types > 20 μmol / L Compound I-66: 5 types > 20 μmol / L Compound I-126: 5 types > 20 μmol / L Compound I-130: 5 types > 20 μmol / L Compound I-141: 5 types > 20 μmol / L Compound I-142: 5 types > 20 μmol / L Compound I-147: 5 types > 20 μmol / L Compound I-151: 5 types > 20 μmol / L

[0115] Test Example 8: BA Test Oral Absorbability Evaluation Experimental Materials and Methods (1) Animals used: Mice or SD rats were used. (2) Feeding conditions: Mice or SD rats were allowed to freely consume solid feed and sterilized tap water. (3) Delivery amount and group setting: Oral delivery and intravenous delivery are delivered at a predetermined delivery amount. Groups are set as follows. (The delivery amount of each compound is subject to change) Oral delivery is 1 to 30 mg / kg (n=2 to 3) 0.5 to 10 mg / kg delivered intravenously (n=2 to 3) (4) Preparation of delivery solution: Oral delivery is delivered in the form of a solution or suspension. Intravenous delivery is delivered in the form of a solubilized solution. (5) Delivery method: Oral delivery is forced delivery into the stomach through an oral sonde. Intravenous delivery is delivery through the tail vein or thigh vein using a syringe with an injection needle. (6) Evaluation parameters: Blood was collected over time, and the concentration of the compound of the present invention in plasma was measured using LC / MS / MS. (7) Statistical analysis: The area under the plasma concentration-time curve (AUC) was calculated using the nonlinear least squares program WinNonlin (registered trademark) for the concentration transition of the compound of the present invention in plasma. The bioavailability (BA) of the compound of the present invention was calculated from the AUC of the oral delivery group and the intravenous delivery group. (result) Compound I-6: 55.1% Compound I-20: 63.4% Compound I-33: 60.5% Compound I-46: 53.1% Compound I-58: 88.2% Compound I-137: 49% Compound I-141: 67% Compound I-142: 66.2%

[0116] Test Example 9: CYP3A4 (MDZ) MBI Test The CYP3A4 inhibition of the compounds of the present invention is a test to evaluate the mechanism based inhibition (MBI) ability from the enhancement caused by metabolic reactions. CYP3A4 inhibition is evaluated using pooled human liver microsomes and the 1-hydroxylation reaction of midazolam (MDZ) as an indicator. The reaction conditions are as follows: substrate: 10 μmol / L MDZ; pre-reaction time: 0 or 30 minutes; reaction time: 2 minutes; reaction temperature: 37°C; combined human liver microsomes: 0.5 mg / mL in pre-reaction, 0.05 mg / mL (at 10-fold dilution) in reaction; concentration of the compound of the present invention in pre-reaction: 1, 5, 10, 20 μmol / L (4 points). In a 96-well plate, a pooled human liver microsome and a solution of the compound of the present invention were added to a K-Pi buffer (pH 7.4) as a pre-reaction solution, and a portion was transferred to another 96-well plate in a manner of diluting the substrate and K-Pi buffer by 1 / 10, and NADPH, which is a coenzyme, was added to start a reaction as an index (without pre-reaction). After a predetermined reaction time, the reaction was stopped by adding a methanol / acetonitrile = 1 / 1 (V / V) solution. Furthermore, NADPH was also added to the remaining pre-reaction solution to start a pre-reaction (with pre-reaction). After a predetermined reaction time, a portion was transferred to another plate in a manner of diluting the substrate and K-Pi buffer by 1 / 10, and a reaction as an index was started. After a predetermined reaction time, the reaction was stopped by adding a methanol / acetonitrile = 1 / 1 (V / V) solution. After the plate after each index reaction was centrifuged at 3000 rpm for 15 minutes, 1-hydroxymidazolam in the centrifuged supernatant was quantified by LC / MS / MS. The reaction system in which only DMSO, which is a solvent for dissolving the compound of the present invention, was added was used as a control group (100%), and the residual activity (%) when the compound of the present invention was added at various concentrations was calculated. The IC was calculated by reverse estimation using a logarithmic model using the concentration and inhibition rate. The IC of 0 minutes of preincubation / IC of 30 minutes of preincubation was used as the shifted IC value. If the shifted IC was 1.5 or more, it was set as positive, and if the shifted IC was 1.0 or less, it was set as negative. (result) Compound I-6: Negative Compound I-14: Negative Compound I-20: Negative Compound I-46: Negative Compound I-58: Negative Compound I-66: Negative Compound I-126: Negative Compound I-130: Negative Compound I-147: Negative Compound I-151: Negative

[0117] Test Example 10: Powder Solubility Test Add the compound of the present invention in an appropriate container in an appropriate amount, and add 200 μL of JP-1 solution (add water to 2.0 g of sodium chloride and 7.0 mL of hydrochloric acid to make 1000 mL), JP-2 solution (add 500 mL of water to 500 mL of pH 6.8 phosphate buffer), and 20 mmol / L sodium taurocholate (TCA) / JP-2 solution (add JP-2 solution to 1.08 g of TCA to make 100 mL) to each container. When the test solution is fully dissolved after addition, add the compound of the present invention appropriately. Seal and shake at 37°C for 1 hour, then filter, and add 100 μL of methanol to each filtrate 100 μL for 2-fold dilution. The dilution ratio and dilution solvent are changed as needed. Confirm the presence of bubbles and precipitates, seal and shake. Quantify the compound of the present invention using HPLC using the absolute calibration curve method. Compound I-46: JP-2 solution 8.64 μmol / L

[0118] Test Example 11: Fluctuation Ames Test Compounds of the invention were evaluated for mutagenicity. 20 μL of frozen Salmonella typhimurium (Salmonella typhimurium TA98 strain, TA100 strain) was inoculated into 10 mL of liquid nutrient medium (2.5% Oxoid nutrient broth No. 2) and pre-cultured at 37°C with shaking for 10 hours. For TA98 strain, 8.0 mL of bacterial solution was centrifuged (2000×g, 10 minutes) and the culture medium was removed. The bacteria were suspended in 8.0 mL of Micro F buffer (K2HPO4: 3.5 g / L, KH2PO4: 1 g / L, (NH4)2SO4: 1 g / L, trisodium citrate dihydrate: 0.25 g / L, MgSO4·7H20: 0.1 g / L) and added to 120 mL of Exposure medium (Micro F buffer containing biotin: 8 μg / mL, histidine: 0.2 μg / mL, glucose: 8 mg / mL). For the TA100 strain, 120 mL of the Exposure medium was added to 3.1 mL of the bacterial solution to prepare a test bacterial solution. 12 μL of each of the following solutions: a DMSO solution of the compound of the present invention (diluted in 2- to 3-fold ratios from the highest dose of 50 mg / mL), DMSO as a negative control, a 50 μg / mL DMSO solution of 4-nitroquinoline-1-oxide for TA98 strain and a 0.25 μg / mL DMSO solution of 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide for TA100 strain under non-metabolism activation conditions as a positive control, a 40 μg / mL DMSO solution of 2-aminoanthracene for TA98 strain and a 20 μg / mL DMSO solution of 2-aminoanthracene for TA100 strain under metabolism activation conditions were mixed with 588 μL of the test bacterial solution (a mixture of 498 μL of the test bacterial solution and 90 μL of S9 mix under metabolism activation conditions), and cultured with shaking at 37°C for 90 minutes. 230 μL of the bacterial solution exposed to the compound of the present invention was mixed with 1150 μL of an indicator medium (MicroF buffer containing biotin: 8 μg / mL, histidine: 0.2 μg / mL, glucose: 8 mg / mL, and bromocresol purple: 37.5 μg / mL), and 50 μL of each was dispensed into 48 wells of a microplate per dosage, and statically cultured at 37°C for 3 days. The wells containing bacteria that have acquired the ability to proliferate by sudden mutation of the amino acid (histidine) synthetase gene change color from purple to yellow due to pH change, so the bacterial proliferation wells that changed color to yellow in 48 wells per dosage were counted and compared with the negative control group for evaluation. Mutagenicity was negative as (-), and positive as (+). Compound I-33: (-)

[0119] Test Example 12: hERG Test For the purpose of evaluating the risk of prolonging the QT interval of the electrocardiogram of the compounds of the present invention, CHO cells expressing the human ether-a-go-go related gene (hERG) channel were used to examine the effects of the compounds of the present invention on the delayed rectifier K, which plays an important role in the process of ventricular repolarization. + The effect of current (Ikr). The cells were maintained at a membrane potential of -80 mV by whole-cell patch clamping using a fully automated patch clamp system (QPatch; Sophion Bioscience A / S). After a leak potential of -50 mV was applied, a depolarization stimulus of +20 mV was applied for 2 seconds, and a repolarization stimulus of -50 mV was further applied for 2 seconds to record the induced IKr. After the generated current stabilized, an extracellular solution (NaCl: 145 mmol / L, KCl: 4 mmol / L, CaCl2: 2 mmol / L, MgCl2: 1 mmol / L, glucose: 10 mmol / L, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid): 10 mmol / L, pH = 7.4) containing the compound of the present invention dissolved at a target concentration was applied to the cells for 10 minutes at room temperature. From the obtained IKr, the absolute value of the maximum tail current was measured using analysis software (Falster Patch; Sophion Bioscience A / S) with the current value at the maintained membrane potential as the reference. Furthermore, the inhibition rate was calculated relative to the maximum tail current before application of the compound of the present invention to evaluate the effect of the compound of the present invention on Ikr. (Results) show the inhibition rate at a compound concentration of 10 μmol / L. Compound I-20: 27.8% Compound I-33: 21.3% Compound I-66: 14.6% Compound I-79: 25.5% Compound I-14: 25.5% Compound I-126: 14.2% Compound I-130: 15.4% Compound I-137: 23.6% Compound I-141: 14.0% Compound I-142: 10.6% Compound I-147: 21.6% Compound I-151: 25.8%

[0120] Test Example 13 (Solution Stability Test) 0.4 mg of the compound of the present invention was weighed in a 4 mL screw bottle, and 2 mL of each medium pH = 1 (0.1N HClaq. + 30% MeCN), pH = 7 (pH7 phosphate buffer (100mM + 30% MeCN), pH = 9 (pH9 carbonate buffer (100mM + 30% MeCN) was added. Complete dissolution was confirmed. If there was no dissolution, it was filtered using a 0.45 μm filter. The solution or filtrate was added to the HPLC bottle. The sample cooler of the HPLC was set to 40°C, and a sequence was established using HPLC by sampling at 0, 3, 6, 9, 12, 15, and 18 hours. The area value of the sample at 0 hour was set to 100%, and the stability over time was evaluated. (result) Residual rate of compound I-3 at 40°C for 18 hours: pH = 1 100.2%, pH = 7 100.9%, pH = 9 100.2%

[0121] Preparation Examples The compounds of the present invention can be delivered by any existing route, especially enteral, for example, in the form of tablets or capsules when oral, or in the form of injection solutions or suspensions when parenteral, in the form of detergents, gels, ointments or emulsions when local, or in the form of nasal or suppositories. The pharmaceutical composition of the compound of the present invention containing a free form or a pharmaceutically acceptable salt form is prepared together with at least one pharmaceutically acceptable carrier or diluent, and can be manufactured by mixing, granulating or coating methods by previous methods. For example, oral compositions can be made into tablets, granules, and capsules containing excipients, disintegrants, binders, lubricants, etc. and active ingredients. Furthermore, the composition for injection can be made into a solution or suspension, and can also be sterilized. Furthermore, it can also contain a preservative, a stabilizer, a buffering agent, etc. [Industrial Applicability]

[0122] Since the compound of the present invention has an MGAT2 inhibitory activity, it is useful as a drug for diseases associated with MGAT2, such as obesity, metabolic syndrome, hyperlipidemia, high lipidemia, hyperVLDLemia, hyperfatty acidemia, diabetes, and arteriosclerosis.

Claims

1. A compound or a pharmaceutically acceptable salt thereof, the compound being selected from the group consisting of the following compounds I-006, I-013, I-014, I-020, I-033, I-046, I-058, I-061, I-066, I-079, I-123, I-124, I-126, I-130, I-133, I-136, I-137, I-139, I-141, I-142, I-143, I-145, I-147, I-121, I-129, I-131 and I-138:

2. A compound selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof:

3. A compound selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof:

4. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following formula:

5. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following formula:

6. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following formula:

7. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following formula:

8. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following formula:

9. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is represented by the following formula:

10. A pharmaceutical composition comprising the compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof.

11. Use of the compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof in the preparation of an agent for treating or preventing obesity.

12. Use of the pharmaceutical composition according to claim 10 in preparing a therapeutic or preventive agent for obesity.

Images